<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ELIQUIS- apixabanÂ tablet, film coatedÂ </strong><br>Cardinal Health<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use ELIQUIS safely and effectively. See full prescribing information for ELIQUIS.<br><br>ELIQUIS<span class="Sup">Â®</span> (apixaban) tablets for oral use<br>Initial U.S. Approval: 2012</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS<br>(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if ELIQUIS is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy. (<a href="#s2.5">2.5</a>, <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">5.1</a>, <a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">14.1</a>)</span> </p>
<p class="Highlighta"><span class="Bold">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span>: Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">(5.3)</a></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta"><a href="#ID_4b7b5ac6-87a7-485a-b13e-6651b4b6e67f">Boxed Warning</a>Â Â Â Â Â 8/2014<br>Indications and Usage <a href="#ID_87e8f549-5689-49c7-a574-42a32ceb0c12">(1.2)</a>Â Â Â Â Â  3/2014<br>Indications and Usage (<a href="#ID_6feb5874-8796-407f-a183-0c18fc7b8cae">1.3</a>, <a href="#ID_4a536824-608b-49d7-b16d-3387bc2d5ddf">1.4</a>, <a href="#ID_6f624d78-06b4-48be-88a2-0b9f274516de">1.5</a>)Â Â Â Â Â 8/2014<br>Dosage and Administration <a href="#s2.1">(2.1)</a>Â Â Â Â Â 8/2014<br>Dosage and Administration <a href="#ID_ad152d54-1c94-48c6-9890-9a35399e1157">(2.8)</a>Â Â Â Â Â 3/2014<br>Warnings and Precautions <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">(5.1)</a>Â Â Â Â Â 8/2014<br>Warnings and Precautions <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">(5.3)</a>Â Â Â Â Â 3/2014<br>Warnings and Precautions <a href="#ID_486900b3-4814-4606-8da8-2111894cacff">(5.5)</a>Â Â Â Â Â 8/2014 </p></div>
</div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS<br>(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></h1>
<h1 class="Warning"><span class="Italics">See full prescribing information for complete boxed warning.</span></h1>
<p class="Highlighta"><span class="Bold">(A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS: Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. To reduce this risk, consider coverage with another anticoagulant if ELIQUIS is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy. (<a href="#s2.5">2.5</a>, <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">5.1</a>, <a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">14.1</a>)</span> </p>
<p class="Highlighta"><span class="Bold">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span>: Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">(5.3)</a></span> </p>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">ELIQUIS is a factor Xa inhibitor anticoagulant indicated: </p>
<dl>
<dt>â€¢</dt>
<dd>to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>. <a href="#ID_748bf08c-1c39-4ef3-a127-67b6e147f799">(1.1)</a>
</dd>
<dt>â€¢</dt>
<dd>for the prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), which may lead to <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), in patients who have undergone hip or knee replacement surgery. <a href="#ID_87e8f549-5689-49c7-a574-42a32ceb0c12">(1.2)</a>
</dd>
<dt>â€¢</dt>
<dd>for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (<a href="#ID_6feb5874-8796-407f-a183-0c18fc7b8cae">1.3</a>, <a href="#ID_4a536824-608b-49d7-b16d-3387bc2d5ddf">1.4</a>, <a href="#ID_6f624d78-06b4-48be-88a2-0b9f274516de">1.5</a>)</dd>
</dl>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Reduction of risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>:<dl>
<dt>â€¢</dt>
<dd>The recommended dose is 5 mg orally twice daily. <a href="#s2.1">(2.1)</a>
</dd>
<dt>â€¢</dt>
<dd>In patients with at least 2 of the following characteristics: age â‰¥80 years, body weight â‰¤60 kg, or serum creatinine â‰¥1.5 mg/dL, the recommended dose is 2.5 mg orally twice daily. <a href="#s2.2">(2.2)</a>
</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Prophylaxis of DVT following hip or knee replacement surgery:<dl>
<dt>â€¢</dt>
<dd>The recommended dose is 2.5 mg orally twice daily. <a href="#s2.1">(2.1)</a>
</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Treatment of DVT and PE:<dl>
<dt>â€¢</dt>
<dd>The recommended dose is 10 mg taken orally twice daily for 7 days, followed by 5 mg taken orally twice daily. <a href="#s2.1">(2.1)</a>
</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd>Reduction in the risk of recurrent DVT and PE following initial therapy:<dl>
<dt>â€¢</dt>
<dd>The recommended dose is 2.5 mg taken orally twice daily. <a href="#s2.1">(2.1)</a>
</dd>
</dl>
</dd>
</dl></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Tablets: 2.5 mg and 5 mg <a href="#s3">(3)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <a href="#s4">(4)</a>
</dd>
<dt>â€¢</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to ELIQUIS <a href="#s4">(4)</a>
</dd>
</dl></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>ELIQUIS can cause serious, potentially fatal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Promptly evaluate signs and symptoms of blood loss. <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">(5.2)</a>
</dd>
<dt>â€¢</dt>
<dd>Prosthetic heart valves: ELIQUIS use not recommended. <a href="#ID_540fc83f-54d6-41ec-bc04-c1b1831cd0e3">(5.4)</a>
</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">Most common adverse reactions (&gt;1%) are related to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">(6.1)</a> </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Bristol-Myers Squibb at 1-800-721-5072 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>Strong dual inhibitors of CYP3A4 and P-gp increase blood levels of apixaban. Reduce dose or avoid coadministration. <a href="#s2.2">(2.2</a>, <a href="#ID_8e0aba69-393f-478b-b422-a499729c12a2">7.1</a>, <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">12.3)</a>
</dd>
<dt>â€¢</dt>
<dd>Simultaneous use of strong dual inducers of CYP3A4 and P-gp reduces blood levels of apixaban: Avoid concomitant use. (<a href="#s2.2">2.2</a>, <a href="#ID_8e0aba69-393f-478b-b422-a499729c12a2">7.2</a>, <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">12.3</a>)</dd>
</dl></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><dl>
<dt>â€¢</dt>
<dd>
<span class="Italics">Pregnancy:</span> Not recommended. <a href="#ID_47163af8-a468-4113-acd7-e6f01f361d71">(8.1)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Nursing Mothers:</span> Discontinue drug or discontinue nursing. <a href="#ID_49c34a2e-e9f2-40b3-94d0-9c14d350890b">(8.3)</a>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Italics">Severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span>:</span> Not recommended. <a href="#ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986">(12.2)</a>
</dd>
</dl></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div><div></div></div>
<div><div></div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 3/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="XmChange">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS</span><br><br><span class="XmChange">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></a></h1>
<h1><a href="#section-1" class="toc">1  INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1 Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></a></h2>
<h2><a href="#section-1.2" class="toc"><span class="XmChange">1.2 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</span></a></h2>
<h2><a href="#section-1.3" class="toc"><span class="XmChange">1.3 Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></span></a></h2>
<h2><a href="#section-1.4" class="toc"><span class="XmChange">1.4 Treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></span></a></h2>
<h2><a href="#section-1.5" class="toc"><span class="XmChange">1.5 Reduction in the Risk of Recurrence of DVT and PE</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION </a></h1>
<h2><a href="#section-2.1" class="toc">2.1 Recommended Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2 Dosage Adjustments</a></h2>
<h2><a href="#section-2.3" class="toc">2.3 Missed Dose</a></h2>
<h2><a href="#section-2.4" class="toc">2.4 Temporary Interruption for Surgery and Other Interventions</a></h2>
<h2><a href="#section-2.5" class="toc">2.5 Converting from or to ELIQUIS</a></h2>
<h2><a href="#section-2.6" class="toc">2.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-2.7" class="toc">2.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.8" class="toc"><span class="XmChange">2.8 Administration Options</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc"><span class="XmChange">5.1  Increased Risk of Thrombotic Events after Premature Discontinuation</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></a></h2>
<h2><a href="#section-5.3" class="toc"><span class="XmChange">5.3 Spinal/Epidural Anesthesia or Puncture</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4 Patients with Prosthetic Heart Valves</a></h2>
<h2><a href="#section-5.5" class="toc"><span class="XmChange">5.5Â Acute PE in Hemodynamically Unstable Patients or Patients who Require <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">Thrombolysis</span> or Pulmonary Embolectomy</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1 Strong Dual Inhibitors of CYP3A4 and P-gp</a></h2>
<h2><a href="#section-7.2" class="toc">7.2 Strong Dual Inducers of CYP3A4 and P-gp</a></h2>
<h2><a href="#section-7.3" class="toc">7.3 Anticoagulants and Antiplatelet Agents</a></h2>
<h1><a href="#section-8" class="toc">8  USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3  Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4  Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> Patients Maintained with Hemodialysis</a></h2>
<h1><a href="#section-9" class="toc">10  OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11  DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-13.1" class="toc">14.1  Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></a></h2>
<h2><a href="#section-13.2" class="toc">14.2  Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</a></h2>
<h2><a href="#section-13.3" class="toc">14.3 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE</a></h2>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17  PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="ID_4b7b5ac6-87a7-485a-b13e-6651b4b6e67f"></a><a name="section-1"></a><p></p>
<h1 style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;">
<span class="XmChange">WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS</span><br><br><span class="XmChange">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span>
</h1>
<p class="First" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="Bold" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">(A) </span>PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS</span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="Bold" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see </span></span><span class="Italics" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><a href="#s2.5">Dosage and Administration (2.5)</a><span class="XmChange">, </span><a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">Warnings and Precautions (5.1)</a><span class="XmChange">, and </span><a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">Clinical Studies (14.1)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">(B) SPINAL/<span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">EPIDURAL HEMATOMA</span></span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange"><span class="Bold">Epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> may result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>. Consider these risks when scheduling patients for spinal procedures. Factors that can increase the risk of developing epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematomas</span> in these patients include:</span></span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="XmChange"><span class="Bold">use of indwelling epidural catheters</span></span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange"><span class="Bold">concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors, other anticoagulants</span></span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange"><span class="Bold">a history of traumatic or repeated epidural or spinal punctures</span></span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange"><span class="Bold">a history of <span class="product-label-link" type="condition" conceptid="73302" conceptname="Curvature of spine">spinal deformity</span> or spinal surgery</span></span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange"><span class="Bold">optimal timing between the administration of ELIQUIS and neuraxial procedures is not known</span></span></dd>
</dl>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="Bold"><span class="Italics" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">[see </span><a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a><span class="XmChange">]</span></span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="Bold" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent treatment is necessary <span class="Italics">[see </span></span><span class="Italics" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></span></p>
<p style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="Bold" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><span class="XmChange">Consider the benefits and risks before neuraxial intervention in patients anticoagulated or to be anticoagulated <span class="Italics">[see </span></span><span class="Italics" style="margin-left:-2em; padding-left:2em; border-left:1px solid; position:relative; zoom: 1;"><a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></span></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1  INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_748bf08c-1c39-4ef3-a127-67b6e147f799"></a><a name="section-1.1"></a><p></p>
<h2>1.1 Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<p class="First">ELIQUIS<span class="Sup">Â®</span> (apixaban) is indicated to reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_87e8f549-5689-49c7-a574-42a32ceb0c12"></a><a name="section-1.2"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.2 Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">ELIQUIS is indicated for the prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span> (DVT), which may lead to <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span> (PE), in patients who have undergone hip or knee replacement surgery.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6feb5874-8796-407f-a183-0c18fc7b8cae"></a><a name="section-1.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.3 Treatment of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">ELIQUIS is indicated for the treatment of DVT.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_4a536824-608b-49d7-b16d-3387bc2d5ddf"></a><a name="section-1.4"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.4 Treatment of <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">Pulmonary Embolism</span></span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">ELIQUIS is indicated for the treatment of PE.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6f624d78-06b4-48be-88a2-0b9f274516de"></a><a name="section-1.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">1.5 Reduction in the Risk of Recurrence of DVT and PE</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">ELIQUIS is indicated to reduce the risk of recurrent DVT and PE following initial therapy.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION </h1>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1 Recommended Dose</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a0062d7d-22d4-4c56-835c-d9edba3c5785"></a><a name="section-2.1.1"></a><p></p>
<h3><span class="Bold">Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></span></h3>
<p class="First">The recommended dose of ELIQUIS for most patients is 5 mg taken orally twice daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c7a6f487-10d0-488f-996c-d7be67c46a0c"></a><a name="section-2.1.2"></a><p></p>
<h3 style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</span></span></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily. The initial dose should be taken 12 to 24 hours after surgery.</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="XmChange">In patients undergoing hip replacement surgery, the recommended duration of treatment is 35 days.</span></dd>
<dt>â€¢</dt>
<dd><span class="XmChange">In patients undergoing knee replacement surgery, the recommended duration of treatment is 12 days.</span></dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c855ddea-1ab2-47c3-9fbb-a04a995ed1fd"></a><a name="section-2.1.3"></a><p></p>
<h3 style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Treatment of DVT and PE</span></span></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dose of ELIQUIS is 10 mg taken orally twice daily for 7 days, followed by 5Â mg taken orally twice daily.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_bf08e643-01cc-4c79-927c-9f3e988a0161"></a><a name="section-2.1.4"></a><p></p>
<h3 style="border-left:1px solid;"><span class="XmChange"><span class="Bold">Reduction in the Risk of Recurrence of DVT and PE</span></span></h3>
<p class="First" style="border-left:1px solid;"><span class="XmChange">The recommended dose of ELIQUIS is 2.5 mg taken orally twice daily after at least 6 months of treatment for DVT or PE <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#ID_6fbc57af-782c-454d-9206-5ff789fe7c5b">Clinical Studies (14.3)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2 Dosage Adjustments</h2>
<p class="First"><span class="Italics">In patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>:</span> The recommended dose of ELIQUIS is 2.5 mg twice daily in patients with any 2 of the following characteristics:</p>
<dl>
<dt>â€¢</dt>
<dd>age â‰¥80 years</dd>
<dt>â€¢</dt>
<dd>body weight â‰¤60 kg</dd>
<dt>â€¢</dt>
<dd>serum creatinine â‰¥1.5 mg/dL</dd>
</dl>
<p><span class="Italics">Coadministration with strong dual CYP3A4 and P-gp inhibitors:</span> For patients receiving ELIQUIS doses greater than 2.5 mg twice daily, reduce the dose by 50% when ELIQUIS is coadministered with drugs that are strong dual inhibitors of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) (e.g., ketoconazole, itraconazole, ritonavir, clarithromycin) <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>In patients already taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with strong dual inhibitors of CYP3A4 and P-gp <span class="Italics">[see <a href="#ID_9dd32361-75eb-49c7-a5c9-f6ec6c14aef9">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3 Missed Dose</h2>
<p class="First">If a dose of ELIQUIS is not taken at the scheduled time, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4 Temporary Interruption for Surgery and Other Interventions</h2>
<p class="First">ELIQUIS should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. ELIQUIS should be discontinued at least 24 hours prior to elective surgery or invasive procedures with a low risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or where the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> would be non-critical in location and easily controlled. Bridging anticoagulation during the 24 to 48 hours after stopping ELIQUIS and prior to the intervention is not generally required. ELIQUIS should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5 Converting from or to ELIQUIS</h2>
<p class="First"><span class="Italics">Switching from warfarin to ELIQUIS:</span> Warfarin should be discontinued and ELIQUIS started when the international normalized ratio (INR) is below 2.0.</p>
<p><span class="Italics">Switching from ELIQUIS to warfarin:</span> ELIQUIS affects INR, so that initial INR measurements during the transition to warfarin may not be useful for determining the appropriate dose of warfarin. If continuous anticoagulation is necessary, discontinue ELIQUIS and begin both a parenteral anticoagulant and warfarin at the time the next dose of ELIQUIS would have been taken, discontinuing the parenteral anticoagulant when INR reaches an acceptable range.</p>
<p><span class="Italics">Switching between ELIQUIS and anticoagulants other than warfarin:</span> Discontinue one being taken and begin the other at the next scheduled dose.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6 <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">No dose adjustment is required in patients with mild <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
<p>Because patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> may have intrinsic coagulation abnormalities and there is limited clinical experience with ELIQUIS in these patients, dosing recommendations cannot be provided <span class="Italics">[see <a href="#ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986">Clinical Pharmacology (12.2)</a>]</span>.</p>
<p>ELIQUIS is not recommended in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>  <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7 <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The dosing adjustment for patients with moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> is described above <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a>]</span>. The recommended dose for nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> (ESRD) maintained on hemodialysis is 5 mg twice daily. Reduce dose to 2.5 mg twice daily if one of the following patient characteristics (age â‰¥80 years or body weight â‰¤60 kg) is present <span class="Italics">[see <a href="#ID_08b58613-14d0-431e-bbd5-fc25b4e4026f">Use in Specific Populations (8.6)</a> and <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>No dose adjustment is required for the following indications:</p>
<dl>
<dt>â€¢</dt>
<dd>for the prophylaxis of  DVT, which may lead to PE, in patients who have undergone hip or knee replacement surgery.</dd>
<dt>â€¢</dt>
<dd>for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_ad152d54-1c94-48c6-9890-9a35399e1157"></a><a name="section-2.8"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">2.8 Administration Options</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">For patients who are unable to swallow whole tablets, 5 mg and 2.5 mg ELIQUIS tablets may be crushed and suspended in 60 mL D5W and immediately delivered through a nasogastric tube (NGT) <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a><span class="XmChange">]</span></span><span class="XmChange">. Information regarding the administration of crushed and suspended ELIQUIS tablets swallowed by mouth is not available.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<dl>
<dt>â€¢</dt>
<dd>2.5 mg, yellow, round, biconvex, film-coated tablets with â€œ893â€? debossed on one side and â€œ2Â½â€? on the other side.</dd>
<dt>â€¢</dt>
<dd>5 mg, pink, oval-shaped, biconvex, film-coated tablets with â€œ894â€? debossed on one side and â€œ5â€? on the other side.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">ELIQUIS is contraindicated in patients with the following conditions:</p>
<dl>
<dt>â€¢</dt>
<dd>Active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a> and <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to ELIQUIS (e.g., <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>) <span class="Italics">[see <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>
</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_7b327732-537f-4c63-a4dd-2a41f437bc25"></a><a name="section-5.1"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.1  Increased Risk of Thrombotic Events after Premature Discontinuation</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Premature discontinuation of any oral anticoagulant, including ELIQUIS, in the absence of adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> was observed during the transition from ELIQUIS to warfarin in clinical trials in <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> patients. If ELIQUIS is discontinued for a reason other than pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or completion of a course of therapy, consider coverage with another anticoagulant <span class="Italics">[see </span></span><span class="Italics" style="border-left:1px solid;"><a href="#s2.5">Dosage and Administration (2.5)</a><span class="XmChange"> and </span><a href="#ID_a7613d0d-0fcb-40e6-9339-beecd55c7497">Clinical Studies (14.1)</a><span class="XmChange">]</span></span><span class="XmChange">.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_b926cbc1-03a8-457d-a907-48ea48aba809"></a><a name="section-5.2"></a><p></p>
<h2>5.2  <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span></h2>
<p class="First">ELIQUIS increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and can cause serious, potentially fatal, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a> and <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>.</p>
<p>Concomitant use of drugs affecting hemostasis increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. These include aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-inflammatory drugs (NSAIDs) <span class="Italics">[see <a href="#ID_db976135-f7e4-4774-b901-842930552cf7">Drug Interactions (7.3)</a>]</span>.</p>
<p>Advise patients of signs and symptoms of blood loss and to report them immediately or go to an emergency room. Discontinue ELIQUIS in patients with active pathological <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>There is no established way to reverse the anticoagulant effect of apixaban, which can be expected to persist for at least 24 hours after the last dose, i.e., for about two drug half-lives. A specific antidote for ELIQUIS is not available. Hemodialysis does not appear to have a substantial impact on apixaban exposure <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>. Protamine sulfate and vitamin K are not expected to affect the anticoagulant activity of apixaban. There is no experience with antifibrinolytic agents (tranexamic acid, aminocaproic acid) in individuals receiving apixaban. There is neither scientific rationale for reversal nor experience with systemic hemostatics (desmopressin and aprotinin) in individuals receiving apixaban. Use of procoagulant reversal agents such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> complex concentrate, activated <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> complex concentrate, or recombinant factor VIIa may be considered but has not been evaluated in clinical studies. Activated oral charcoal reduces absorption of apixaban, thereby lowering apixaban plasma concentration <span class="Italics">[see <a href="#s10">Overdosage (10)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e"></a><a name="section-5.3"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.3 Spinal/Epidural Anesthesia or Puncture</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">When neuraxial anesthesia (spinal/epidural anesthesia) or spinal/epidural puncture is employed, patients treated with antithrombotic agents for prevention of thromboembolic complications are at risk of developing an epidural or spinal <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> which can result in long-term or permanent <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The risk of these events may be increased by the postoperative use of indwelling epidural catheters or the concomitant use of medicinal products affecting hemostasis. Indwelling epidural or intrathecal catheters should not be removed earlier than 24 hours after the last administration of ELIQUIS. The next dose of ELIQUIS should not be administered earlier than 5 hours after the removal of the catheter. The risk may also be increased by traumatic or repeated epidural or spinal puncture. If traumatic puncture occurs, delay the administration of ELIQUIS for 48 hours.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Monitor patients frequently for signs and symptoms of neurological impairment (e.g., <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of the legs, bowel, or bladder dysfunction). If neurological compromise is noted, urgent diagnosis and treatment is necessary. Prior to neuraxial intervention the physician should consider the potential benefit versus the risk in anticoagulated patients or in patients to be anticoagulated for thromboprophylaxis.</span></p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="ID_540fc83f-54d6-41ec-bc04-c1b1831cd0e3"></a><a name="section-5.4"></a><p></p>
<h2>5.4 Patients with Prosthetic Heart Valves</h2>
<p class="First">The safety and efficacy of ELIQUIS have not been studied in patients with prosthetic heart valves. Therefore, use of ELIQUIS is not recommended in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_486900b3-4814-4606-8da8-2111894cacff"></a><a name="section-5.5"></a><p></p>
<h2 style="border-left:1px solid;"><span class="XmChange">5.5Â Acute PE in Hemodynamically Unstable Patients or Patients who Require <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">Thrombolysis</span> or Pulmonary Embolectomy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Initiation of ELIQUIS is not recommended as an alternative to unfractionated heparin for the initial treatment of patients with PE who present with <span class="product-label-link" type="condition" conceptid="4311860" conceptname="Hemodynamic instability">hemodynamic instability</span> or who may receive <span class="product-label-link" type="condition" conceptid="4196955" conceptname="Thrombolysis">thrombolysis</span> or pulmonary embolectomy.</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">The following serious adverse reactions are discussed in greater detail in other sections of the prescribing information.</p>
<dl>
<dt>â€¢</dt>
<dd>Increased risk of thrombotic events after premature discontinuation <span class="Italics">[see <a href="#ID_7b327732-537f-4c63-a4dd-2a41f437bc25">Warnings and Precautions (5.1)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>
</dd>
<dt>â€¢</dt>
<dd>Spinal/epidural anesthesia or puncture <span class="Italics">[see <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a>]</span>
</dd>
</dl>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_fb7e3c59-041f-45be-81a1-f6d6724d3617"></a><a name="section-6.1.1"></a><p></p>
<h3><span class="Bold">Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></span></h3>
<p class="First">The safety of ELIQUIS was evaluated in the ARISTOTLE and AVERROES studies <span class="Italics">[see <a href="#s14">Clinical Studies (14)</a>]</span>, including 11,284 patients exposed to ELIQUIS 5 mg twice daily and 602 patients exposed to ELIQUIS 2.5 mg twice daily. The duration of ELIQUIS exposure was â‰¥12 months for 9375 patients and â‰¥24 months for 3369 patients in the two studies. In ARISTOTLE, the mean duration of exposure was 89 weeks (&gt;15,000 patient-years). In AVERROES, the mean duration of exposure was approximately 59 weeks (&gt;3000 patient-years).</p>
<p>The most common reason for treatment discontinuation in both studies was for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>-related adverse reactions; in ARISTOTLE this occurred in 1.7% and 2.5% of patients treated with ELIQUIS and warfarin, respectively, and in AVERROES, in 1.5% and 1.3% on ELIQUIS and aspirin, respectively.</p>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_943d572f-8a88-4111-8007-366bc830d096"></a><a name="section-6.1.1.1"></a><p></p>
<h4><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in ARISTOTLE and AVERROES</span></h4>
<p class="First">Tables 1 and 2 show the number of patients experiencing major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during the treatment period and the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> rate (percentage of subjects with at least one <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> event per year) in ARISTOTLE and AVERROES.</p>
<p><span class="Italics">Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span> was defined as clinically overt <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that was accompanied by one or more of the following: a decrease in hemoglobin of 2 g/dL or more; a transfusion of 2 or more units of packed red blood cells; <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that occurred in at least one of the following critical sites: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with <span class="product-label-link" type="condition" conceptid="134734" conceptname="Compartment syndrome">compartment syndrome</span>, retroperitoneal; or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that was fatal. <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">Intracranial hemorrhage</span> included intracerebral (<span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>), subarachnoid, and subdural bleeds.</p>
<a name="_RefID0EB3AE"></a><table width="100%">
<caption><span>Table 1:Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in ARISTOTLE</span></caption>
<col width="25%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="15%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS</span><br><span class="Bold">N=9088</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Warfarin</span><br><span class="Bold">N=9052</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Hazard Ratio</span><br><span class="Bold">(95% CI*)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">P-value</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="5" valign="top">*Â Â Confidence interval.<br><span class="Sup">â€ </span>Â Â Â International Society on <span class="product-label-link" type="condition" conceptid="4130722" conceptname="Thrombosis">Thrombosis</span> and Hemostasis (ISTH) major bleed assessed by sequential testing strategy for superiority designed to control the overall type I error in the trial.<br><span class="Sup">â€¡</span>Â Â Â <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">GI bleed</span> includes upper GI, lower GI, and <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span>.<br><span class="Sup">Â§</span>Â Â Â Intraocular bleed is within the corpus of the eye (a conjunctival bleed is not an intraocular bleed).<br><span class="Sup">Â¶</span>Â Â Â Fatal bleed is an adjudicated <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> because of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> during the treatment period and includes both fatal extracranial bleeds and fatal <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span>.<br>**Â CRNM = clinically relevant nonmajor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.<br>Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Major<span class="Sup">â€ </span></p></td>
<td class="Toprule" align="center"><p class="First">327 (2.13)</p></td>
<td class="Toprule" align="center"><p class="First">462 (3.09)</p></td>
<td class="Toprule" align="center"><p class="First">0.69 (0.60, 0.80)</p></td>
<td class="Toprule" align="center"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Gastrointestinal (GI)<span class="Sup">â€¡</span></p></td>
<td align="center"><p class="First">128 (0.83)</p></td>
<td align="center"><p class="First">141 (0.93)</p></td>
<td align="center"><p class="First">0.89 (0.70, 1.14)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Intracranial</p></td>
<td align="center"><p class="First">52 (0.33)</p></td>
<td align="center"><p class="First">125 (0.82)</p></td>
<td align="center"><p class="First">0.41 (0.30, 0.57)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Intraocular<span class="Sup">Â§</span></p></td>
<td align="center"><p class="First">32 (0.21)</p></td>
<td align="center"><p class="First">22 (0.14)</p></td>
<td align="center"><p class="First">1.42 (0.83, 2.45)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Fatal<span class="Sup">Â¶</span></p></td>
<td align="center"><p class="First">10 (0.06)</p></td>
<td align="center"><p class="First">37 (0.24)</p></td>
<td align="center"><p class="First">0.27 (0.13, 0.53)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">CRNM**</p></td>
<td class="Botrule" align="center"><p class="First">318 (2.08)</p></td>
<td class="Botrule" align="center"><p class="First">444 (3.00)</p></td>
<td class="Botrule" align="center"><p class="First">0.70 (0.60, 0.80)</p></td>
<td class="Botrule" align="center"><p class="First">&lt;0.0001</p></td>
</tr>
</tbody>
</table>
<p>In ARISTOTLE, the results for major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were generally consistent across most major subgroups including age, weight, CHADS<span class="Sub">2</span> score (a scale from 0 to 6 used to estimate risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, with higher scores predicting greater risk), prior warfarin use, geographic region, ELIQUIS dose, type of <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (AF), and aspirin use at randomization (Figure 1). Subjects treated with apixaban with <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> bled more (3.0% per year) than did subjects without <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> (1.9% per year).</p>
<p>Figure <a href="#_Ref">1</a>:Â Â Â Â Â Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Hazard Ratios by Baseline Characteristics â€“ ARISTOTLE Study</p>
<div class="Figure">
<a name="id15689367"></a><img alt="ARISTOTLE Major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Forest Plot" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=eliquis-forest-fig1.jpg"><p class="MultiMediaCaption">Table 2: Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in AVERROES</p>
</div>
<a name="_RefID0E5BAG"></a><table width="100%">
<caption><span>Table 2: Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Events in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in AVERROES</span></caption>
<col width="25%">
<col width="20%">
<col width="20%">
<col width="20%">
<col width="15%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS</span><br><span class="Bold">N=2798</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Aspirin</span><br><span class="Bold">N=2780</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Hazard Ratio</span><br><span class="Bold">(95% CI)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">P-value</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="10" valign="top">Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Major</p></td>
<td class="Toprule" align="center"><p class="First">45 (1.41)</p></td>
<td class="Toprule" align="center"><p class="First">29 (0.92)</p></td>
<td class="Toprule" align="center"><p class="First">1.54 (0.96, 2.45)</p></td>
<td class="Toprule" align="center"><p class="First">0.07</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Fatal</p></td>
<td align="center"><p class="First">5 (0.16)</p></td>
<td align="center"><p class="First">5 (0.16)</p></td>
<td align="center"><p class="First">0.99 (0.23, 4.29)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Â Â Â Â Intracranial</p></td>
<td class="Botrule" align="center"><p class="First">11 (0.34)</p></td>
<td class="Botrule" align="center"><p class="First">11 (0.35)</p></td>
<td class="Botrule" align="center"><p class="First">0.99 (0.39, 2.51)</p></td>
<td class="Botrule" align="center"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="ID_e1d9695c-0bf3-420a-b1ee-34ac719f2c7d"></a><a name="section-6.1.1.2"></a><p></p>
<h4><span class="Bold">Other Adverse Reactions</span></h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> (including <span class="product-label-link" type="condition" conceptid="439224" conceptname="Drug allergy">drug hypersensitivity</span>, such as <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>, such as allergic <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>) and <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span> were reported in &lt;1% of patients receiving ELIQUIS.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_72af8d8f-3b4e-4258-8836-bd0e77435d4a"></a><a name="section-6.1.2"></a><p></p>
<h3><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</span></h3>
<p class="First">The safety of ELIQUIS has been evaluated in 1 Phase II and 3 Phase III studies including 5924 patients exposed to ELIQUIS 2.5 mg twice daily undergoing major orthopedic surgery of the lower limbs (elective hip replacement or elective knee replacement) treated for up to 38 days.</p>
<p>In total, 11% of the patients treated with ELIQUIS 2.5 mg twice daily experienced adverse reactions.</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> results during the treatment period in the Phase III studies are shown in Table 3. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> was assessed in each study beginning with the first dose of double-blind study drug.</p>
<a name="_RefID0EQGAG"></a><table width="100%">
<caption><span>Table 3:Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> During the Treatment Period in Patients Undergoing Elective Hip or Knee Replacement Surgery</span></caption>
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<col width="14%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Endpoint*</span></th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top">
<span class="Bold">ADVANCE-3</span><br><span class="Bold">Hip Replacement Surgery</span>
</th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="2" valign="top">
<span class="Bold">ADVANCE-2</span><br><span class="Bold">Knee Replacement Surgery</span>
</th>
<th class="Botrule Lrule Toprule" align="left" colspan="2" valign="top">
<span class="Bold">ADVANCE-1</span><br><span class="Bold">Knee Replacement Surgery</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="7" valign="top">*Â Â Â All <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> criteria included surgical site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.<br><span class="Sup">â€ </span>Â Â Â Includes 13 subjects with major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).<br><span class="Sup">â€¡</span>Â Â Â Includes 5 subjects with major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events that occurred before the first dose of apixaban (administered 12 to 24 hours post surgery).<br><span class="Sup">Â§</span>Â Â Â Intracranial, intraspinal, intraocular, pericardial, an operated joint requiring re-operation or intervention, intramuscular with <span class="product-label-link" type="condition" conceptid="134734" conceptname="Compartment syndrome">compartment syndrome</span>, or retroperitoneal. <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> into an operated joint requiring re-operation or intervention was present in all patients with this category of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Events and event rates include one enoxaparin-treated patient in ADVANCE-1 who also had <span class="product-label-link" type="condition" conceptid="439847" conceptname="Intracranial hemorrhage">intracranial hemorrhage</span>.<br><span class="Sup">Â¶</span>Â Â Â CRNM = clinically relevant nonmajor.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Rrule Toprule" rowspan="2"></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">ELIQUIS<br>2.5 mg po bid<br>35Â±3 days</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Enoxaparin <br>40 mg sc qd <br>35Â±3 days</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">ELIQUIS <br>2.5 mg po bid <br>12Â±2 days</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">Enoxaparin <br>40 mg sc qd <br>12Â±2 days</p></td>
<td class="Lrule Rrule Toprule" align="center"><p class="First">ELIQUIS <br>2.5 mg po bid <br>12Â±2 days</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">Enoxaparin <br>30 mg sc q12h 12Â±2 days</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="center"><p class="First">First dose <br>12 to 24 hours post surgery</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">First dose <br>9 to 15 hours prior to surgery</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">First dose <br>12 to 24 hours post surgery</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">First dose <br>9 to 15 hours prior to surgery</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">First dose <br>12 to 24 hours post surgery</p></td>
<td class="Botrule Lrule" align="center"><p class="First">First dose <br>12 to 24 hours post surgery</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">All treated</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=2673</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=2659</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=1501</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=1508</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">N=1596</p></td>
<td class="Botrule Lrule" align="center"><p class="First">N=1588</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Major (including surgical site)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">22 (0.82%)<span class="Sup">â€ </span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">18 (0.68%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (0.60%)<span class="Sup">â€¡</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14 (0.93%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (0.69%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">22 (1.39%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Fatal</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0</p></td>
<td class="Botrule Lrule" align="center"><p class="First">1 (0.06%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Hgb decrease â‰¥2Â g/dL</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">13 (0.49%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 (0.38%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">8 (0.53%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (0.60%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">10 (0.63%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">16 (1.01%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Transfusion of â‰¥2 units RBC</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16 (0.60%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">14 (0.53%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (0.33%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (0.60%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (0.56%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">18 (1.13%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Bleed at critical site<span class="Sup">Â§</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.04%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.04%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.07%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (0.13%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.06%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">4 (0.25%)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Major<br>+ CRNM<span class="Sup">Â¶</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">129 (4.83%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">134 (5.04%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">53 (3.53%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">72 (4.77%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">46 (2.88%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">68 (4.28%)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">All</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">313 (11.71%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">334 (12.56%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">104 (6.93%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">126 (8.36%)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">85 (5.33%)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">108 (6.80%)</p></td>
</tr>
</tbody>
</table>
<p>Adverse reactions occurring in â‰¥1% of patients undergoing hip or knee replacement surgery in the 1 Phase II study and the 3 Phase III studies are listed in Table 4.</p>
<a name="_RefID0EFTAG"></a><table width="100%">
<caption><span>Table 4:Â Â Â  Â Adverse Reactions Occurring in â‰¥1% of Patients in Either Group Undergoing Hip or Knee Replacement Surgery</span></caption>
<col width="55%">
<col width="20%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS, n (%) </span><br><span class="Bold">2.5 mg po bid </span><br><br><span class="Bold">N=5924</span>
</th>
<th class="Botrule Lrule Toprule" align="left" valign="top">
<span class="Bold">Enoxaparin, n (%) </span><br><span class="Bold">40 mg sc qd or </span><br><span class="Bold">30 mg sc q12h </span><br><span class="Bold">N=5904</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">153 (2.6)</p></td>
<td class="Botrule Lrule Toprule" align="center"><p class="First">159 (2.7)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span> (including postoperative and <span class="product-label-link" type="condition" conceptid="434894" conceptname="Acute posthemorrhagic anemia">hemorrhagic anemia</span>, and respective laboratory parameters)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">153 (2.6)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">178 (3.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">83 (1.4)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">115 (1.9)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Hemorrhage</span> (including <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, and vaginal and <span class="product-label-link" type="condition" conceptid="4096556" conceptname="Bleeding from urethra">urethral hemorrhage</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">67 (1.1)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">81 (1.4)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Postprocedural <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (including postprocedural <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4343234" conceptname="Wound hemorrhage">wound hemorrhage</span>, vessel puncture site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> and catheter site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">54 (0.9)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">60 (1.0)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Transaminases increased (including <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> increased and <span class="product-label-link" type="condition" conceptid="4211515" conceptname="Alanine aminotransferase">alanine aminotransferase</span> abnormal)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">50 (0.8)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">71 (1.2)</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">Aspartate aminotransferase</span> increased</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">47 (0.8)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">69 (1.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">Gamma-glutamyltransferase increased</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">38 (0.6)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">65 (1.1)</p></td>
</tr>
</tbody>
</table>
<p>Less common adverse reactions in apixaban-treated patients undergoing hip or knee replacement surgery occurring at a frequency of â‰¥0.1% to &lt;1%:</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> (including platelet count decreases)</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> (including procedural <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>)</p>
<p><span class="Italics">Respiratory, thoracic, and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">mediastinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span> (including <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span> and <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>), <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span></p>
<p><span class="Italics">Hepatobiliary disorders:</span> <span class="product-label-link" type="condition" conceptid="438878" conceptname="Liver function tests abnormal">liver function test abnormal</span>, blood alkaline phosphatase increased, blood bilirubin increased</p>
<p><span class="Italics">Renal and urinary disorders:</span> <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span> (including respective laboratory parameters)</p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, and procedural complications:</span> <span class="product-label-link" type="condition" conceptid="4343235" conceptname="Wound discharge">wound secretion</span>, incision-site <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> (including incision-site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>), <span class="product-label-link" type="condition" conceptid="4308716" conceptname="Intraoperative hemorrhage">operative hemorrhage</span></p>
<p>Less common adverse reactions in apixaban-treated patients undergoing hip or knee replacement surgery occurring at a frequency of &lt;0.1%:</p>
<p><span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">Gingival bleeding</span>, <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>, <span class="product-label-link" type="condition" conceptid="4317281" conceptname="Hemorrhage of muscle">muscle hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">ocular hemorrhage</span> (including <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>), <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_75a2c4e9-34d0-420b-bb27-396a6aea58a1"></a><a name="section-6.1.3"></a><p></p>
<h3><span class="Bold">Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT or PE</span></h3>
<p class="First">The safety of ELIQUIS has been evaluated in the AMPLIFY and AMPLIFY-EXT studies, including 2676 patients exposed to ELIQUIS 10 mg twice daily, 3359 patients exposed to ELIQUIS 5 mg twice daily, and 840 patients exposed to ELIQUIS 2.5 mg twice daily.</p>
<p>Common adverse reactions (â‰¥1%) were <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">contusion</span>, <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">hematuria</span>, <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">menorrhagia</span>, and <span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">hemoptysis</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_a3997a8b-697a-44f3-9ef3-f14efa442fe5"></a><a name="section-6.1.3.1"></a><p></p>
<h4><span class="Bold">AMPLIFY Study</span></h4>
<p class="First">The mean duration of exposure to ELIQUIS was 154 days and to enoxaparin/warfarin was 152 days in the AMPLIFY study. Adverse reactions related to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurred in 417 (15.6%) ELIQUIS-treated patients compared to 661 (24.6%) enoxaparin/warfarin-treated patients. The discontinuation rate due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events was 0.7% in the ELIQUIS-treated patients compared to 1.7% in enoxaparin/warfarin-treated patients in the AMPLIFY study.</p>
<p>In the AMPLIFY study, ELIQUIS was statistically superior to enoxaparin/warfarin in the primary safety endpoint of major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (relative risk 0.31, 95% CI [0.17, 0.55], P-value &lt;0.0001).</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> results from the AMPLIFY study are summarized in Table 5.</p>
<a name="_RefID0EKZAG"></a><table width="100%">
<caption><span>Table 5:Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Results in the AMPLIFY Study</span></caption>
<col width="20%">
<col width="20%">
<col width="25%">
<col width="35%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">N=2676</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Enoxaparin/Warfarin</span><br><span class="Bold">N=2689</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Relative Risk (95% CI)</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Â CRNM = clinically relevant nonmajor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.<br>Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Major</p></td>
<td class="Toprule" align="center"><p class="First">15 (0.6)</p></td>
<td class="Toprule" align="center"><p class="First">49 (1.8)</p></td>
<td class="Toprule" align="center"><p class="First">0.31 (0.17, 0.55)<br>p&lt;0.0001</p></td>
</tr>
<tr>
<td><p class="First">CRNM*</p></td>
<td align="center"><p class="First">103 (3.9)</p></td>
<td align="center"><p class="First">215 (8.0)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Major + CRNM</p></td>
<td align="center"><p class="First">115 (4.3)</p></td>
<td align="center"><p class="First">261 (9.7)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Minor</p></td>
<td align="center"><p class="First">313 (11.7)</p></td>
<td align="center"><p class="First">505 (18.8)</p></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">All</p></td>
<td class="Botrule" align="center"><p class="First">402 (15.0)</p></td>
<td class="Botrule" align="center"><p class="First">676 (25.1)</p></td>
<td class="Botrule"></td>
</tr>
</tbody>
</table>
<p>Adverse reactions occurring in â‰¥1% of patients in the AMPLIFY study are listed in Table 6.</p>
<a name="_RefID0EU3AG"></a><table width="100%">
<caption><span>Table 6:Â Â Â Â Â Adverse Reactions Occurring in â‰¥1% of Patients Treated for DVT and PE in the AMPLIFY Study</span></caption>
<col width="33%">
<col width="33%">
<col width="33%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">N=2676 </span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Enoxaparin/Warfarin </span><br><span class="Bold">N=2689 </span><br><span class="Bold">n (%)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Toprule" align="center"><p class="First">77 (2.9)</p></td>
<td class="Toprule" align="center"><p class="First">146 (5.4)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></p></td>
<td align="center"><p class="First">49 (1.8)</p></td>
<td align="center"><p class="First">Â 97 (3.6)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td align="center"><p class="First">46 (1.7)</p></td>
<td align="center"><p class="First">102 (3.8)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">Menorrhagia</span></p></td>
<td align="center"><p class="First">38 (1.4)</p></td>
<td align="center"><p class="First">Â 30 (1.1)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></p></td>
<td align="center"><p class="First">35 (1.3)</p></td>
<td align="center"><p class="First">Â 76 (2.8)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="261687" conceptname="Hemoptysis">Hemoptysis</span></p></td>
<td align="center"><p class="First">32 (1.2)</p></td>
<td align="center"><p class="First">Â 31 (1.2)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">Rectal hemorrhage</span></p></td>
<td align="center"><p class="First">26 (1.0)</p></td>
<td align="center"><p class="First">Â 39 (1.5)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">Gingival bleeding</span></p></td>
<td class="Botrule" align="center"><p class="First">26 (1.0)</p></td>
<td class="Botrule" align="center"><p class="First">Â 50 (1.9)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_0e695f73-6870-4a38-bba8-be344d6bc241"></a><a name="section-6.1.3.2"></a><p></p>
<h4><span class="Bold">AMPLIFY-EXT Study</span></h4>
<p class="First">The mean duration of exposure to ELIQUIS was approximately 330 days and to placebo was 312 days in the AMPLIFY-EXT study. Adverse reactions related to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurred in 219 (13.3%) ELIQUIS-treated patients compared to 72 (8.7%) placebo-treated patients. The discontinuation rate due to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> events was approximately 1% in the ELIQUIS-treated patients compared to 0.4% in those patients in the placebo group in the AMPLIFY-EXT study.</p>
<p><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> results from the AMPLIFY-EXT study are summarized in Table 7.</p>
<a name="_RefID0EQABG"></a><table width="100%">
<caption><span>Table 7:Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> Results in the AMPLIFY-EXT Study</span></caption>
<col width="20%">
<col width="20%">
<col width="25%">
<col width="35%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS 2.5 mg </span><br><span class="Bold">N=840</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS 5 mg </span><br><span class="Bold">N=811</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">N=826</span><br><span class="Bold">n (%)</span>
</th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Â CRNM = clinically relevant nonmajor <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.<br>Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">Major</p></td>
<td class="Toprule" align="center"><p class="First">2 (0.2)</p></td>
<td class="Toprule" align="center"><p class="First">1 (0.1)</p></td>
<td class="Toprule" align="center"><p class="First">4 (0.5)</p></td>
</tr>
<tr>
<td><p class="First">CRNM*</p></td>
<td align="center"><p class="First">25 (3.0)</p></td>
<td align="center"><p class="First">34 (4.2)</p></td>
<td align="center"><p class="First">19 (2.3)</p></td>
</tr>
<tr>
<td><p class="First">Major + CRNM</p></td>
<td align="center"><p class="First">27 (3.2)</p></td>
<td align="center"><p class="First">35 (4.3)</p></td>
<td align="center"><p class="First">22 (2.7)</p></td>
</tr>
<tr>
<td><p class="First">Minor</p></td>
<td align="center"><p class="First">75 (8.9)</p></td>
<td align="center"><p class="First">98 (12.1)</p></td>
<td align="center"><p class="First">58 (7.0)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">All</p></td>
<td class="Botrule" align="center"><p class="First">94 (11.2)</p></td>
<td class="Botrule" align="center"><p class="First">121 (14.9)</p></td>
<td class="Botrule" align="center"><p class="First">74 (9.0)</p></td>
</tr>
</tbody>
</table>
<p>Adverse reactions occurring in â‰¥1% of patients in the AMPLIFY-EXT study are listed in TableÂ 8.</p>
<a name="_RefID0EHEBG"></a><table width="100%">
<caption><span>Table 8:Â Â Â Â Â Adverse Reactions Occurring in â‰¥1% of Patients Undergoing Extended Treatment for DVT and PE in the AMPLIFY-EXT Study</span></caption>
<col width="25%">
<col width="25%">
<col width="25%">
<col width="25%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS 2.5 mg</span><br><span class="Bold">N=840 </span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS 5 mg</span><br><span class="Bold">N=811</span><br><span class="Bold">n (%)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Placebo </span><br><span class="Bold">N=826 </span><br><span class="Bold">n (%)</span>
</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></p></td>
<td class="Toprule" align="center"><p class="First">13 (1.5)</p></td>
<td class="Toprule" align="center"><p class="First">29 (3.6)</p></td>
<td class="Toprule" align="center"><p class="First">9 (1.1)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></p></td>
<td align="center"><p class="First">12 (1.4)</p></td>
<td align="center"><p class="First">17 (2.1)</p></td>
<td align="center"><p class="First">9 (1.1)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></p></td>
<td align="center"><p class="First">13 (1.5)</p></td>
<td align="center"><p class="First">16 (2.0)</p></td>
<td align="center"><p class="First">10 (1.2)</p></td>
</tr>
<tr>
<td><p class="First"><span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">Contusion</span></p></td>
<td align="center"><p class="First">18 (2.1)</p></td>
<td align="center"><p class="First">18 (2.2)</p></td>
<td align="center"><p class="First">18 (2.2)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First"><span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">Gingival bleeding</span></p></td>
<td class="Botrule" align="center"><p class="First">12 (1.4)</p></td>
<td class="Botrule" align="center"><p class="First">9 (1.1)</p></td>
<td class="Botrule" align="center"><p class="First">3 (0.4)</p></td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_9236cf90-c496-4b29-97ab-134ee555f2a2"></a><a name="section-6.1.3.3"></a><p></p>
<h4><span class="Bold">Other Adverse Reactions</span></h4>
<p class="First">Less common adverse reactions in ELIQUIS-treated patients in the AMPLIFY or AMPLIFY-EXT studies occurring at a frequency of â‰¥0.1% to &lt;1%:</p>
<p><span class="Italics">Blood and lymphatic system disorders:</span> <span class="product-label-link" type="condition" conceptid="434894" conceptname="Acute posthemorrhagic anemia">hemorrhagic anemia</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">hematochezia</span>, <span class="product-label-link" type="condition" conceptid="4198840" conceptname="Bleeding hemorrhoids">hemorrhoidal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="192671" conceptname="Gastrointestinal hemorrhage">gastrointestinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="26727" conceptname="Hematemesis">hematemesis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="4245614" conceptname="Bleeding from anus">anal hemorrhage</span></p>
<p><span class="Italics">Injury, <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span>, and procedural complications:</span> <span class="product-label-link" type="condition" conceptid="4343234" conceptname="Wound hemorrhage">wound hemorrhage</span>, postprocedural <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4149692" conceptname="Subungual hematoma">traumatic hematoma</span>, <span class="product-label-link" type="condition" conceptid="4193496" conceptname="Periorbital hematoma">periorbital hematoma</span></p>
<p><span class="Italics">Musculoskeletal and <span class="product-label-link" type="condition" conceptid="253549" conceptname="Disorder of connective tissue">connective tissue disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4317281" conceptname="Hemorrhage of muscle">muscle hemorrhage</span></p>
<p><span class="Italics">Reproductive system and <span class="product-label-link" type="condition" conceptid="77030" conceptname="Disorder of breast">breast disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="195012" conceptname="Intermenstrual bleeding - irregular">metrorrhagia</span>, <span class="product-label-link" type="condition" conceptid="4151132" conceptname="Menometrorrhagia">menometrorrhagia</span>, genital <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="443784" conceptname="Vascular disorder">Vascular disorders</span></span>: <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></p>
<p><span class="Italics">Skin and subcutaneous tissue disorders:</span> <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymosis</span>, skin <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378756" conceptname="Conjunctival hemorrhage">conjunctival hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span>, <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span></p>
<p><span class="Italics">Investigations:</span> <span class="product-label-link" type="condition" conceptid="437038" conceptname="Blood in urine">blood urine present</span>, occult blood positive, occult blood, <span class="product-label-link" type="condition" conceptid="4090004" conceptname="RBCs- red blood cells in urine">red blood cells urine positive</span></p>
<p><span class="Italics">General disorders and administration-site conditions:</span> injection-site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, vessel puncture-site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span></p>
</div>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First">Apixaban is a substrate of both CYP3A4 and P-gp. Inhibitors of CYP3A4 and P-gp increase exposure to apixaban and increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Inducers of CYP3A4 and P-gp decrease exposure to apixaban and increase the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and other <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">thromboembolic events</span>.</p>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_9dd32361-75eb-49c7-a5c9-f6ec6c14aef9"></a><a name="section-7.1"></a><p></p>
<h2>7.1 Strong Dual Inhibitors of CYP3A4 and P-gp</h2>
<p class="First">For patients receiving ELIQUIS doses greater than 2.5 mg twice daily, the dose of ELIQUIS should be decreased by 50% when it is coadministered with drugs that are strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, itraconazole, ritonavir, or clarithromycin) <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a> and <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>
<p>For patients receiving ELIQUIS at a dose of 2.5 mg twice daily, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp <span class="Italics">[see <a href="#s2.2">Dosage and Administration (2.2)</a> and <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_8e0aba69-393f-478b-b422-a499729c12a2"></a><a name="section-7.2"></a><p></p>
<h2>7.2 Strong Dual Inducers of CYP3A4 and P-gp</h2>
<p class="First">Avoid concomitant use of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g., rifampin, carbamazepine, phenytoin, St. Johnâ€™s wort) because such drugs will decrease exposure to apixaban <span class="Italics">[see <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="ID_db976135-f7e4-4774-b901-842930552cf7"></a><a name="section-7.3"></a><p></p>
<h2>7.3 Anticoagulants and Antiplatelet Agents</h2>
<p class="First">Coadministration of antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic NSAID use increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</p>
<p>APPRAISE-2, a placebo-controlled clinical trial of apixaban in high-risk, post-<span class="product-label-link" type="condition" conceptid="4215140" conceptname="Acute coronary syndrome">acute coronary syndrome</span> patients treated with aspirin or the combination of aspirin and clopidogrel, was terminated early due to a higher rate of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> with apixaban compared to placebo. The rate of ISTH major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was 2.77% per year with apixaban versus 0.62% per year with placebo in patients receiving single antiplatelet therapy and was 5.91% per year with apixaban versus 2.50% per year with placebo in those receiving dual antiplatelet therapy.</p>
<p>In ARISTOTLE, concomitant use of aspirin increased the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk on ELIQUIS from 1.8% per year to 3.4% per year and the <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> risk on warfarin from 2.7% per year to 4.6% per year. In this clinical trial, there was limited (2.3%) use of dual antiplatelet therapy with ELIQUIS.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s8"></a><a name="section-8"></a><p></p>
<h1>8  USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="ID_47163af8-a468-4113-acd7-e6f01f361d71"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="ID_bed144a3-c52e-44d0-8037-bf749f8cb2ee"></a><a name="section-8.1.1"></a><p></p>
<h3><span class="Bold">Pregnancy Category B</span></h3>
<p class="First">There are no adequate and well-controlled studies of ELIQUIS in pregnant women. Treatment is likely to increase the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> during pregnancy and delivery. ELIQUIS should be used during pregnancy only if the potential benefit outweighs the potential risk to the mother and fetus.</p>
<p>Treatment of pregnant rats, rabbits, and mice after implantation until the end of gestation resulted in fetal exposure to apixaban, but was not associated with increased risk for <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> or toxicity. No maternal or <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal deaths</span> were attributed to <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Increased incidence of maternal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> was observed in mice, rats, and rabbits at maternal exposures that were 19, 4, and 1 times, respectively, the human exposure of unbound drug, based on area under plasma-concentration time curve (AUC) comparisons at the maximum recommended human dose (MRHD) of 10 mg (5 mg twice daily).</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="ID_7428b6f8-df88-4d43-a02c-df6f5952471e"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<p class="First">Safety and effectiveness of ELIQUIS during labor and delivery have not been studied in clinical trials. Consider the risks of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> and of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in using ELIQUIS in this setting <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>.</p>
<p>Treatment of pregnant rats from implantation (gestation Day 7) to weaning (lactation Day 21) with apixaban at a dose of 1000 mg/kg (about 5 times the human exposure based on unbound apixaban) did not result in <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of offspring or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of mother rats during labor in association with <span class="product-label-link" type="condition" conceptid="195876" conceptname="Hematometra">uterine bleeding</span>. However, increased incidence of maternal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, primarily during gestation, occurred at apixaban doses of â‰¥25 mg/kg, a dose corresponding to â‰¥1.3 times the human exposure.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="ID_49c34a2e-e9f2-40b3-94d0-9c14d350890b"></a><a name="section-8.3"></a><p></p>
<h2>8.3  Nursing Mothers</h2>
<p class="First">It is unknown whether apixaban or its metabolites are excreted in human milk. Rats excrete apixaban in milk (12% of the maternal dose).</p>
<p>Women should be instructed either to discontinue breastfeeding or to discontinue ELIQUIS therapy, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="ID_bf3844a3-6a1d-4ec6-8223-6a94850812bd"></a><a name="section-8.4"></a><p></p>
<h2>8.4  Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="ID_241a3258-7bb0-43c0-b080-944566bf98df"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">Of the total subjects in the ARISTOTLE and AVERROES clinical studies, &gt;69% were 65 and older, and &gt;31% were 75 and older. In the ADVANCE-1, ADVANCE-2, and ADVANCE-3 clinical studies, 50% of subjects were 65 and older, while 16% were 75 and older. In the AMPLIFY and AMPLIFY-EXT clinical studies, &gt;32% of subjects were 65 and older and &gt;13% were 75 and older. No clinically significant differences in safety or effectiveness were observed when comparing subjects in different age groups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_08b58613-14d0-431e-bbd5-fc25b4e4026f"></a><a name="section-8.6"></a><p></p>
<h2>8.6 End-Stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">Renal Disease</span> Patients Maintained with Hemodialysis</h2>
<p class="First">Patients with ESRD with or without hemodialysis were not studied in clinical efficacy and safety studies with ELIQUIS; therefore, the dosing recommendation for patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> is based on pharmacokinetic and pharmacodynamic (anti-Factor Xa activity) data in subjects with ESRD maintained on dialysis. The recommended dose for ESRD patients maintained with hemodialysis is 5 mg orally twice daily. For ESRD patients maintained with hemodialysis with one of the following patient characteristics, age â‰¥80 years or body weight â‰¤60 kg, reduce dose to 2.5 mg twice daily <span class="Italics">[see <a href="#s2.7">Dosage and Administration (2.7)</a> and <a href="#ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986">Clinical Pharmacology (12.2</a>, <a href="#ID_0138578a-a58b-4cad-b354-271d6b1854d1">12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s10"></a><a name="section-9"></a><p></p>
<h1>10  OVERDOSAGE</h1>
<p class="First">There is no antidote to ELIQUIS. <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of ELIQUIS increases the risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>.</p>
<p>In controlled clinical trials, orally administered apixaban in healthy subjects at doses up to 50 mg daily for 3 to 7 days (25 mg twice daily for 7 days or 50 mg once daily for 3 days) had no clinically relevant adverse effects.</p>
<p>In healthy subjects, administration of activated charcoal 2 and 6 hours after ingestion of a 20-mg dose of apixaban reduced mean apixaban AUC by 50% and 27%, respectively. Thus, administration of activated charcoal may be useful in the management of apixaban <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> or accidental ingestion.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s11"></a><a name="section-10"></a><p></p>
<h1>11  DESCRIPTION</h1>
<p class="First">ELIQUIS (apixaban), a factor Xa (FXa) inhibitor, is chemically described as 1-(4-methoxyphenyl)-7-oxo-6-[4-(2-oxopiperidin-1-yl)phenyl]-4,5,6,7-tetrahydro-1<span class="Italics">H</span>-pyrazolo[3,4-<span class="Italics">c</span>]pyridine-3-carboxamide. Its molecular formula is C<span class="Sub">25</span>H<span class="Sub">25</span>N<span class="Sub">5</span>O<span class="Sub">4</span>, which corresponds to a molecular weight of 459.5. Apixaban has the following structural formula:</p>
<div class="Figure">
<a name="id15675537"></a><img alt="Apixaban Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=apixaban-struct.jpg">
</div>
<p>Apixaban is a white to <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span>-yellow powder. At physiological pH (1.2â€“6.8), apixaban does not ionize; its aqueous solubility across the physiological pH range is ~0.04 mg/mL.</p>
<p>ELIQUIS tablets are available for oral administration in strengths of 2.5 mg and 5 mg of apixaban with the following inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="ID_0dba7108-252d-45bc-a285-d1a47eb77b40"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_ffcee25e-6f0f-469c-84d4-4258bdd2d986"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">As a result of FXa inhibition, apixaban prolongs clotting tests such as <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time (PT), INR, and <span class="product-label-link" type="condition" conceptid="44809202" conceptname="Activated partial thromboplastin time">activated partial thromboplastin time</span> (aPTT). Changes observed in these clotting tests at the expected therapeutic dose, however, are small, subject to a high degree of variability, and not useful in monitoring the anticoagulation effect of apixaban.</p>
<p>The Rotachrom<span class="Sup">Â®</span> Heparin chromogenic assay was used to measure the effect of apixaban on FXa activity in humans during the apixaban development program. A concentration-dependent increase in anti-FXa activity was observed in the dose range tested and was similar in healthy subjects and patients with AF.</p>
<p>This test is not recommended for assessing the anticoagulant effect of apixaban.</p>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_8c166241-72a8-4ee0-98e6-2ccb79faca6c"></a><a name="section-11.2.1"></a><p></p>
<h3><span class="Bold">Pharmacodynamic Drug Interaction Studies</span></h3>
<p class="First">Pharmacodynamic drug interaction studies with aspirin, clopidogrel, aspirin and clopidogrel, prasugrel, enoxaparin, and naproxen were conducted. No <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interactions</span> were observed with aspirin, clopidogrel, or prasugrel <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a>]</span>. A 50% to 60% increase in anti-FXa activity was observed when apixaban was coadministered with enoxaparin or naproxen.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_3d52486b-82e3-41c3-b9e2-65e3991507fc"></a><a name="section-11.2.2"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<p class="First"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Anti-FXa activity adjusted for exposure to apixaban was similar across renal function categories.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> Changes in anti-FXa activity were similar in patients with mild-to-moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> and healthy subjects. However, in patients with moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, there is no clear understanding of the impact of this degree of hepatic function impairment on the coagulation cascade and its relationship to efficacy and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> were not studied.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="ID_e8488ae6-28be-4be8-a489-56a361918589"></a><a name="section-11.2.3"></a><p></p>
<h3><span class="Bold">Cardiac Electrophysiology</span></h3>
<p class="First">Apixaban has no effect on the QTc interval in humans at doses up to 50 mg.</p>
</div>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_0138578a-a58b-4cad-b354-271d6b1854d1"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">Apixaban demonstrates linear pharmacokinetics with dose-proportional increases in exposure for oral doses up to 10 mg.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_ec69f4ee-86ee-4e9e-862a-36791e769688"></a><a name="section-11.3.1"></a><p></p>
<h3><span class="Bold">Absorption</span></h3>
<p class="First">The absolute bioavailability of apixaban is approximately 50% for doses up to 10 mg of ELIQUIS. Food does not affect the bioavailability of apixaban. Maximum concentrations (C<span class="Sub">max</span>) of apixaban appear 3 to 4 hours after oral administration of ELIQUIS. At doses â‰¥25 mg, apixaban displays dissolution-limited absorption with decreased bioavailability. Following administration of a crushed 5 mg ELIQUIS tablet that was suspended in 60 mL D5W and delivered through a nasogastric tube (NGT), exposure was similar to that seen in other clinical trials involving healthy volunteers receiving a single oral 5 mg tablet dose.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_eac74eab-a357-493f-aecd-ae962268230f"></a><a name="section-11.3.2"></a><p></p>
<h3><span class="Bold">Distribution</span></h3>
<p class="First">Plasma protein binding in humans is approximately 87%. The volume of distribution (Vss) is approximately 21 liters.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_f1071a5b-3a44-480d-ade8-14f548cb1d88"></a><a name="section-11.3.3"></a><p></p>
<h3><span class="Bold">Metabolism</span></h3>
<p class="First">Approximately 25% of an orally administered apixaban dose is recovered in urine and feces as metabolites. Apixaban is metabolized mainly via CYP3A4 with minor contributions from CYP1A2, 2C8, 2C9, 2C19, and 2J2. O-demethylation and hydroxylation at the 3-oxopiperidinyl moiety are the major sites of biotransformation.</p>
<p>Unchanged apixaban is the major drug-related component in human plasma; there are no active circulating metabolites.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_e8e775ce-ad39-4a0a-9d25-45ddd1d2153d"></a><a name="section-11.3.4"></a><p></p>
<h3><span class="Bold">Elimination</span></h3>
<p class="First">Apixaban is eliminated in both urine and feces. Renal excretion accounts for about 27% of total clearance. Biliary and direct intestinal excretion contributes to elimination of apixaban in the feces.</p>
<p>Apixaban has a total clearance of approximately 3.3 L/hour and an apparent half-life of approximately 12 hours following oral administration.</p>
<p>Apixaban is a substrate of transport proteins: P-gp and breast cancer resistance protein.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_c4cbfa56-4b06-4991-acc2-88b1ee619240"></a><a name="section-11.3.5"></a><p></p>
<h3><span class="Bold">Drug Interaction Studies</span></h3>
<p class="First"><span class="Italics">In vitro</span> apixaban studies at concentrations significantly greater than therapeutic exposures, no inhibitory effect on the activity of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2D6, CYP3A4/5, or CYP2C19, nor induction effect on the activity of CYP1A2, CYP2B6, or CYP3A4/5 were observed. Therefore, apixaban is not expected to alter the metabolic clearance of coadministered drugs that are metabolized by these enzymes. Apixaban is not a significant inhibitor of P-gp.</p>
<p>The effects of coadministered drugs on the pharmacokinetics of apixaban and associated dose recommendations are summarized in Figure 2 <span class="Italics">[see also <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a> and <a href="#s7">Drug Interactions (7)</a>]</span>.</p>
<p>Figure <a href="#_Ref">2</a>: Â Â Â Â Â Effect of Coadministered Drugs on the Pharmacokinetics of Apixaban</p>
<div class="Figure">
<a name="id6195948"></a><img alt="Effect of drugs on PK" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=eliquis-pkplot-drugs-fig2.jpg">
</div>
<p>Â Â Â Â Â Â Â Â *Â Â Dashed vertical lines illustrate pharmacokinetic changes that were used to inform<br>Â Â Â Â Â Â Â Â Â Â Â Â dosing recommendations. Dosing recommendations were also informed by<br>Â Â Â Â Â Â Â Â Â Â Â Â clinical considerations <span class="Italics">[see <a href="#ID_b926cbc1-03a8-457d-a907-48ea48aba809">Warnings and Precautions (5.2)</a> and <a href="#s7">Drug Interactions (7)</a>]</span>.</p>
<p>In dedicated studies conducted in healthy subjects, famotidine, atenolol, prasugrel, and enoxaparin did not meaningfully alter the pharmacokinetics of apixaban.</p>
<p>In studies conducted in healthy subjects, apixaban did not meaningfully alter the pharmacokinetics of digoxin, naproxen, atenolol, prasugrel, or acetylsalicylic acid.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="ID_31f13068-b6ac-44d1-8d24-eb05503bcdce"></a><a name="section-11.3.6"></a><p></p>
<h3><span class="Bold">Specific Populations</span></h3>
<p class="First">The effects of level of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, age, body weight, and level of <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> on the pharmacokinetics of apixaban are summarized in Figure 3.</p>
<p>Figure <a href="#_Ref">3</a>: Â Â Â Â Â Effect of Specific Populations on the Pharmacokinetics of Apixaban</p>
<div class="Figure">
<a name="id15674025"></a><img alt="Effect of Populations on PK" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=eliquis-pkplot-pop-fig3.jpg">
</div>
<p>Â Â Â Â Â Â Â Â *Â Â ESRD subjects maintained with chronic and stable hemodialysis; reported PK findings <br>Â Â Â Â Â Â Â Â Â Â Â Â are following single dose of apixaban post hemodialysis.<br>Â Â Â Â Â Â Â Â <span class="Sup">â€ </span>Â Â Creatinine clearance 15 to 29 mL/min.<br>Â Â Â Â Â Â Â Â <span class="Sup">â€¡</span>Â Â Dashed vertical lines illustrate pharmacokinetic changes that were used to inform <br>Â Â Â Â Â Â Â Â Â Â Â Â dosing recommendations.</p>
<p>A study in healthy subjects comparing the pharmacokinetics in males and females showed no meaningful difference.</p>
<p>The results across pharmacokinetic studies in normal subjects showed no differences in apixaban pharmacokinetics among White/Caucasian, Asian, and Black/African American subjects. No dose adjustment is required based on race/ethnicity.</p>
<p>In subjects with ESRD, a 4-hour hemodialysis session with a dialysate flow rate of 500 mL/min and a blood flow rate in the range of 350 to 500 mL/min started 2 hours after administration of a single 5 mg dose of apixaban, the AUC of apixaban was 17% greater compared to those with normal renal function. The dialysis clearance of apixaban is approximately 18 mL/min resulting in a 14% decrease in exposure due to hemodialysis compared to off-dialysis period.</p>
<p>Protein binding was similar (92%-94%) between healthy controls and the on-dialysis and off-dialysis periods.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="ID_63b61b63-cdb1-49f3-bf28-6bbac58b34c5"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First"><span class="Italics">Carcinogenesis:</span> Apixaban was not carcinogenic when administered to mice and rats for up to 2 years. The systemic exposures (AUCs) of unbound apixaban in male and female mice at the highest doses tested (1500 and 3000 mg/kg/day) were 9 and 20 times, respectively, the human exposure of unbound drug at the MRHD of 10 mg/day. Systemic exposures of unbound apixaban in male and female rats at the highest dose tested (600 mg/kg/day) were 2 and 4 times, respectively, the human exposure.</p>
<p><span class="Italics">Mutagenesis:</span> Apixaban was neither mutagenic in the bacterial reverse mutation (Ames) assay, nor clastogenic in Chinese hamster ovary cells <span class="Italics">in vitro</span>, in a 1-month <span class="Italics">in vivo/in vitro</span> cytogenetics study in rat peripheral blood <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span>, or in a rat micronucleus study <span class="Italics">in vivo</span>.</p>
<p><span class="Italics">Impairment of Fertility:</span> Apixaban had no effect on fertility in male or female rats when given at doses up to 600 mg/kg/day, a dose resulting in exposure levels that are 3 and 4 times, respectively, the human exposure.</p>
<p>Apixaban administered to female rats at doses up to 1000 mg/kg/day from implantation through the end of lactation produced no adverse findings in male offspring (F<span class="Sub">1</span> generation) at doses up to 1000 mg/kg/day, a dose resulting in exposure that is 5 times the human exposure. Adverse effects in the F<span class="Sub">1</span>-generation female offspring were limited to decreased mating and fertility indices at 1000 mg/kg/day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_a7613d0d-0fcb-40e6-9339-beecd55c7497"></a><a name="section-13.1"></a><p></p>
<h2>14.1  Reduction of Risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_f2b61ad8-875a-4be4-8703-e24e8ec80fee"></a><a name="section-13.1.1"></a><p></p>
<h3><span class="Bold">ARISTOTLE</span></h3>
<p class="First">Evidence for the efficacy and safety of ELIQUIS was derived from ARISTOTLE, a multinational, double-blind study in patients with nonvalvular AF comparing the effects of ELIQUIS and warfarin on the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and non-central nervous system (CNS) systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. In ARISTOTLE, patients were randomized to ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in subjects with at least 2 of the following characteristics: age â‰¥80 years, body weight â‰¤60 kg, or serum creatinine â‰¥1.5 mg/dL) or to warfarin (targeted to an INR range of 2.0â€“3.0). Patients had to have one or more of the following additional risk factors for <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>:</p>
<dl>
<dt>â€¢</dt>
<dd>prior <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or transient ischemic attack (TIA)</dd>
<dt>â€¢</dt>
<dd>prior systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></dd>
<dt>â€¢</dt>
<dd>age â‰¥75 years</dd>
<dt>â€¢</dt>
<dd>arterial <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> requiring treatment</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> â‰¥New York Heart Association Class 2</dd>
<dt>â€¢</dt>
<dd>left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤40%</dd>
</dl>
<p>The primary objective of ARISTOTLE was to determine whether ELIQUIS 5 mg twice daily (or 2.5 mg twice daily) was effective (noninferior to warfarin) in reducing the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> (ischemic or hemorrhagic) and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. Superiority of ELIQUIS to warfarin was also examined for the primary endpoint (rate of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>), major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> from any cause.</p>
<p>A total of 18,201 patients were randomized and followed on study treatment for a median of 89 weeks. Forty-three percent of patients were vitamin K antagonist (VKA) â€œnaive,â€? defined as having received â‰¤30 consecutive days of treatment with warfarin or another VKA before entering the study. The mean age was 69 years and the mean CHADS<span class="Sub">2</span> score (a scale from 0 to 6 used to estimate risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, with higher scores predicting greater risk) was 2.1. The population was 65% male, 83% Caucasian, 14% Asian, and 1% Black. There was a history of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, TIA, or non-CNS systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> in 19% of patients. Concomitant diseases of patients in this study included <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> 88%, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> 25%, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> (or left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> â‰¤40%) 35%, and prior <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> 14%. Patients treated with warfarin in ARISTOTLE had a mean percentage of time in therapeutic range (INR 2.0â€“3.0) of 62%.</p>
<p>ELIQUIS was superior to warfarin for the primary endpoint of reducing the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> (Table 9 and Figure 4). Superiority to warfarin was primarily attributable to a reduction in <span class="product-label-link" type="condition" conceptid="4046362" conceptname="Hemorrhagic cerebral infarction">hemorrhagic stroke</span> and <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic strokes</span> with hemorrhagic conversion compared to warfarin. Purely <span class="product-label-link" type="condition" conceptid="4310996" conceptname="Ischemic stroke">ischemic strokes</span> occurred with similar rates on both drugs.</p>
<p>ELIQUIS also showed significantly fewer major bleeds than warfarin <span class="Italics">[see <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>.</p>
<a name="_RefID0EBCAI"></a><table width="100%">
<caption><span>Table 9:Â Â Â Â Â Key Efficacy Outcomes in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in ARISTOTLE (Intent-to-Treat Analysis)</span></caption>
<col width="43%">
<col width="14%">
<col width="14%">
<col width="16%">
<col width="13%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS</span><br><span class="Bold">N=9120</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Warfarin</span><br><span class="Bold">N=9081</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Hazard Ratio</span><br><span class="Bold">(95% CI)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">P-value</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="5" valign="top">The primary endpoint was based on the time to first event (one per subject). Component counts are for subjects with any event, not necessarily the first.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></p></td>
<td class="Toprule" align="center"><p class="First">212 (1.27)</p></td>
<td class="Toprule" align="center"><p class="First">265 (1.60)</p></td>
<td class="Toprule" align="center"><p class="First">0.79 (0.66, 0.95)</p></td>
<td class="Toprule" align="center"><p class="First">0.01</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p></td>
<td align="center"><p class="First">199 (1.19)</p></td>
<td align="center"><p class="First">250 (1.51)</p></td>
<td align="center"><p class="First">0.79 (0.65, 0.95)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Ischemic without <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span></p></td>
<td align="center"><p class="First">140 (0.83)</p></td>
<td align="center"><p class="First">136 (0.82)</p></td>
<td align="center"><p class="First">1.02 (0.81, 1.29)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Ischemic with hemorrhagic conversion</p></td>
<td align="center"><p class="First">12 (0.07)</p></td>
<td align="center"><p class="First">20 (0.12)</p></td>
<td align="center"><p class="First">0.60 (0.29, 1.23)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Hemorrhagic</p></td>
<td align="center"><p class="First">40 (0.24)</p></td>
<td align="center"><p class="First">78 (0.47)</p></td>
<td align="center"><p class="First">0.51 (0.35, 0.75)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Unknown</p></td>
<td align="center"><p class="First">14 (0.08)</p></td>
<td align="center"><p class="First">21 (0.13)</p></td>
<td align="center"><p class="First">0.65 (0.33, 1.29)</p></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Â Â Â Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></p></td>
<td class="Botrule" align="center"><p class="First">15 (0.09)</p></td>
<td class="Botrule" align="center"><p class="First">17 (0.10)</p></td>
<td class="Botrule" align="center"><p class="First">0.87 (0.44, 1.75)</p></td>
<td class="Botrule"></td>
</tr>
</tbody>
</table>
<p>Figure <a href="#_Ref">4</a>: Â Â Â Â Â Kaplan-Meier Estimate of Time to First <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> in ARISTOTLE (Intent-to-Treat Population)</p>
<div class="Figure">
<a name="id20059188"></a><img alt="ARISTOTLE Kaplan-Meier Curve" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=eliquis-km-fig4.jpg">
</div>
<p>All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> was assessed using a sequential testing strategy that allowed testing for superiority if effects on earlier endpoints (<span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> plus systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolus</span> and major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>) were demonstrated. ELIQUIS treatment resulted in a significantly lower rate of all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (p = 0.046) than did treatment with warfarin, primarily because of a reduction in cardiovascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, particularly <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Non-vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> rates were similar in the treatment arms.</p>
<p>In ARISTOTLE, the results for the primary efficacy endpoint were generally consistent across most major subgroups including weight, CHADS<span class="Sub">2</span> score (a scale from 0 to 6 used to predict risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> in patients with AF, with higher scores predicting greater risk), prior warfarin use, level of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, geographic region, ELIQUIS dose, type of AF, and aspirin use at randomization (Figure 5).</p>
<p>Figure <a href="#_Ref">5</a>: Â Â Â Â Â <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> and Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">Embolism</span> Hazard Ratios by Baseline Characteristics â€“ ARISTOTLE Study</p>
<div class="Figure">
<a name="id15692707"></a><img alt="ARISTOTLE Forest Plot " src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=eliquis-clin-forest-fig5.jpg">
</div>
<p>At the end of the ARISTOTLE study, warfarin patients who completed the study were generally maintained on a VKA with no interruption of anticoagulation. ELIQUIS patients who completed the study were generally switched to a VKA with a 2-day period of coadministration of ELIQUIS and VKA, so that some patients may not have been adequately anticoagulated after stopping ELIQUIS until attaining a stable and therapeutic INR. During the 30 days following the end of the study, there were 21 <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> events in the 6791 patients (0.3%) in the ELIQUIS arm compared to 5 in the 6569 patients (0.1%) in the warfarin arm <span class="Italics">[see <a href="#s2.5">Dosage and Administration (2.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_52748f50-0952-4e20-8d7b-12d454981109"></a><a name="section-13.1.2"></a><p></p>
<h3><span class="Bold">AVERROES</span></h3>
<p class="First">In AVERROES, patients with nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> thought not to be candidates for warfarin therapy were randomized to treatment with ELIQUIS 5 mg orally twice daily (or 2.5 mg twice daily in selected patients) or aspirin 81 to 324 mg once daily. The primary objective of the study was to determine if ELIQUIS was superior to aspirin for preventing the composite outcome of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> or systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span>. AVERROES was stopped early on the basis of a prespecified interim analysis showing a significant reduction in <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span> for ELIQUIS compared to aspirin that was associated with a modest increase in major <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (Table 10) <span class="Italics">[see <a href="#ID_e2e3f133-ee9c-4781-bcd7-3af1586e9ead">Adverse Reactions (6.1)</a>]</span>.</p>
<a name="_RefID0EBJAI"></a><table width="100%">
<caption><span>Table 10: Â Â Â Â Â Key Efficacy Outcomes in Patients with Nonvalvular <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span> in AVERROES</span></caption>
<col width="43%">
<col width="14%">
<col width="14%">
<col width="16%">
<col width="13%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS</span><br><span class="Bold">N=2807</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Aspirin</span><br><span class="Bold">N=2791</span><br><span class="Bold">n (%/year)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Hazard Ratio</span><br><span class="Bold">(95% CI)</span>
</th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">P-value</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First"><span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span> or systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></p></td>
<td class="Toprule" align="center"><p class="First">51 (1.62)</p></td>
<td class="Toprule" align="center"><p class="First">113 (3.63)</p></td>
<td class="Toprule" align="center"><p class="First">0.45 (0.32, 0.62)</p></td>
<td class="Toprule" align="center"><p class="First">&lt;0.0001</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">Stroke</span></p></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Ischemic or undetermined</p></td>
<td align="center"><p class="First">43 (1.37)</p></td>
<td align="center"><p class="First">97 (3.11)</p></td>
<td align="center"><p class="First">0.44 (0.31, 0.63)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Â Â Â Hemorrhagic</p></td>
<td align="center"><p class="First">6 (0.19)</p></td>
<td align="center"><p class="First">9 (0.28)</p></td>
<td align="center"><p class="First">0.67 (0.24, 1.88)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â Systemic <span class="product-label-link" type="condition" conceptid="4185607" conceptname="Embolism">embolism</span></p></td>
<td align="center"><p class="First">2 (0.06)</p></td>
<td align="center"><p class="First">13 (0.41)</p></td>
<td align="center"><p class="First">0.15 (0.03, 0.68)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">MI</p></td>
<td align="center"><p class="First">24 (0.76)</p></td>
<td align="center"><p class="First">28 (0.89)</p></td>
<td align="center"><p class="First">0.86 (0.50, 1.48)</p></td>
<td align="center"><p class="First">-</p></td>
</tr>
<tr>
<td><p class="First">All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td align="center"><p class="First">111 (3.51)</p></td>
<td align="center"><p class="First">140 (4.42)</p></td>
<td align="center"><p class="First">0.79 (0.62, 1.02)</p></td>
<td align="center"><p class="First">0.068</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">Â Â Â Vascular <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule" align="center"><p class="First">84 (2.65)</p></td>
<td class="Botrule" align="center"><p class="First">96 (3.03)</p></td>
<td class="Botrule" align="center"><p class="First">0.87 (0.65, 1.17)</p></td>
<td class="Botrule" align="center"><p class="First">-</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="ID_edafa3f2-e1fb-49b7-8625-a1625bb90464"></a><a name="section-13.2"></a><p></p>
<h2>14.2  Prophylaxis of <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">Deep Vein Thrombosis</span> Following Hip or Knee Replacement Surgery</h2>
<p class="First">The clinical evidence for the effectiveness of ELIQUIS is derived from the ADVANCE-1, ADVANCE-2, and ADVANCE-3 clinical trials in adult patients undergoing elective hip (ADVANCE-3) or knee (ADVANCE-2 and ADVANCE-1) replacement surgery. A total of 11,659 patients were randomized in 3 double-blind, multi-national studies. Included in this total were 1866 patients age 75 or older, 1161 patients with low body weight (â‰¤60 kg), 2528 patients with Body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">Mass</span> Index â‰¥33Â kg/m<span class="Sup">2</span>, and 625 patients with severe or moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
<p>In the ADVANCE-3 study, 5407 patients undergoing elective hip replacement surgery were randomized to receive either ELIQUIS 2.5 mg orally twice daily or enoxaparin 40 mg subcutaneously once daily. The first dose of ELIQUIS was given 12 to 24 hours post surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. Treatment duration was 32 to 38 days.</p>
<p>In patients undergoing elective knee replacement surgery, ELIQUIS 2.5 mg orally twice daily was compared to enoxaparin 40 mg subcutaneously once daily (ADVANCE-2, N=3057) or enoxaparin 30 mg subcutaneously every 12 hours (ADVANCE-1, N=3195). In the ADVANCE-2 study, the first dose of ELIQUIS was given 12 to 24 hours post surgery, whereas enoxaparin was started 9 to 15 hours prior to surgery. In the ADVANCE-1 study, both ELIQUIS and enoxaparin were initiated 12 to 24 hours post surgery. Treatment duration in both ADVANCE-2 and ADVANCE-1 was 10 to 14 days.</p>
<p>In all 3 studies, the primary endpoint was a composite of adjudicated asymptomatic and symptomatic DVT, nonfatal PE, and all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> at the end of the double-blind intended treatment period. In ADVANCE-3 and ADVANCE-2, the primary endpoint was tested for noninferiority, then superiority, of ELIQUIS to enoxaparin. In ADVANCE-1, the primary endpoint was tested for noninferiority of ELIQUIS to enoxaparin.</p>
<p>The efficacy data are provided in Tables 11 and 12.</p>
<a name="_RefID0EEPAI"></a><table width="100%">
<caption><span>Table 11: Â Â Â Â Â Summary of Key Efficacy Analysis Results During the Intended Treatment Period for Patients Undergoing Elective Hip Replacement Surgery*</span></caption>
<col width="42%">
<col width="21%">
<col width="18%">
<col width="19%">
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Â Events associated with each endpoint were counted once per subject but subjects may have contributed events to multiple endpoints.<br><span class="Sup">â€ </span>Â Â Â Total VTE includes symptomatic and asymptomatic DVT and PE.<br><span class="Sup">â€¡</span>Â Â Â Includes symptomatic and asymptomatic DVT.</td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="2"><p class="First"><span class="Bold">ADVANCE-3</span></p></td>
<td class="Botrule Lrule Toprule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Events During 35-Day Treatment Period</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">ELIQUIS<br>2.5 mg po bid</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">Enoxaparin <br>40 mg sc qd</p></td>
<td class="Botrule Lrule" align="center"><p class="First">Relative Risk<br>(95% CI)<br>P-value</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1949</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1917</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Total VTE<span class="Sup">â€ </span>/All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">27 (1.39%)<br>(0.95, 2.02)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">74 (3.86%)<br>(3.08, 4.83)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.36<br>(0.22, 0.54)<br>p&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=2708</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=2699</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.11%)<br>(0.02, 0.35)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.04%)<br>(0.00, 0.24)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â PE</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.11%)<br>(0.02, 0.35)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (0.19%)<br>(0.07, 0.45)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Symptomatic DVT</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1 (0.04%)<br>(0.00, 0.24)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">5 (0.19%)<br>(0.07, 0.45)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=2196</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=2190</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Proximal DVT<span class="Sup">â€¡</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (0.32%)<br>(0.14, 0.68)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 (0.91%)<br>(0.59, 1.42)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1951</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1908</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">Â Â Distal DVT<span class="Sup">â€¡</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">20 (1.03%)<br>(0.66, 1.59)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">57 (2.99%)<br>(2.31, 3.86)</p></td>
<td class="Botrule Lrule"></td>
</tr>
</tbody>
</table>
<a name="_RefID0E1XAI"></a><table width="100%">
<caption><span>Table 12:Â Â Â Â Â Summary of Key Efficacy Analysis Results During the Intended Treatment Period for Patients Undergoing Elective Knee Replacement Surgery*</span></caption>
<col width="17%">
<col width="15%">
<col width="16%">
<col width="12%">
<col width="14%">
<col width="14%">
<col width="12%">
<thead><tr class="First Last">
<th class="Botrule Rrule Toprule" align="left" valign="top"></th>
<th class="Botrule Lrule Rrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">ADVANCE-1</span></th>
<th class="Botrule Lrule Toprule" align="left" colspan="3" valign="top"><span class="Bold">ADVANCE-2</span></th>
</tr></thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="11" valign="top">*Â Â Â Events associated with each endpoint were counted once per subject but subjects may have contributed events to multiple endpoints.<br><span class="Sup">â€ </span>Â Â Â Total VTE includes symptomatic and asymptomatic DVT and PE.<br><span class="Sup">â€¡</span>Â Â Â Includes symptomatic and asymptomatic DVT.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule"><p class="First">Events during <br>12-day treatment period</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">ELIQUIS <br>2.5 mg po bid</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Enoxaparin <br>30 mg sc q12h</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Relative Risk<br> (95% CI)<br>P-value</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">ELIQUIS <br>2.5 mg po bid</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Enoxaparin <br>40 mg sc </p>
<p>qd</p>
</td>
<td class="Botrule Lrule Toprule" align="center">
<p class="First">Relative Risk<br>(95% CI)</p>
<p>P-value</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1157</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1130</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=976</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=997</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Total VTE<span class="Sup">â€ </span>/All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">104 (8.99%) <br>(7.47, 10.79)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">100 (8.85%) <br>(7.33, 10.66)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">1.02<br>(0.78, 1.32)<br>NS</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">147 (15.06%)<br>(12.95, 17.46)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">243 (24.37%) <br>(21.81, 27.14)</p></td>
<td class="Botrule Lrule" align="center"><p class="First">0.62<br>(0.51, 0.74)<br>p&lt;0.0001</p></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1599</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1596</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1528</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1529</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.19%)<br>(0.04, 0.59)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.19%)<br>(0.04, 0.59)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">2 (0.13%)<br>(0.01, 0.52)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0 (0%)<br>(0.00, 0.31)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â PE </p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">16 (1.0%)<br>(0.61, 1.64)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (0.44%)<br>(0.20, 0.93)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">4 (0.26%)<br>(0.08, 0.70)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">0 (0%)<br>(0.00, 0.31)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Symptomatic<br>Â Â DVT</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.19%)<br>(0.04, 0.59)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (0.44%)<br>(0.20, 0.93)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">3 (0.20%)<br>(0.04, 0.61)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">7 (0.46%)<br>(0.20, 0.97)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1254</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1207</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1192</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1199</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First">Â Â Proximal DVT<span class="Sup">â€¡</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (0.72%)<br>(0.36, 1.39)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">11 (0.91%)<br>(0.49, 1.65)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">9 (0.76%)<br>(0.38, 1.46)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">26 (2.17%)<br>(1.47, 3.18)</p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr>
<td class="Botrule Rrule"><p class="First"><span class="Bold">Number of Patients</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1146</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1133</span></p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=978</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First"><span class="Bold">N=1000</span></p></td>
<td class="Botrule Lrule"></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">Â Â Distal DVT<span class="Sup">â€¡</span></p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">83 (7.24%)<br>(5.88, 8.91)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">91 (8.03%)<br>(6.58, 9.78)</p></td>
<td class="Botrule Lrule Rrule"></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">142 (14.52%)<br>(12.45, 16.88)</p></td>
<td class="Botrule Lrule Rrule" align="center"><p class="First">239 (23.9%)<br>(21.36, 26.65)</p></td>
<td class="Botrule Lrule"></td>
</tr>
</tbody>
</table>
<p>The efficacy profile of ELIQUIS was generally consistent across subgroups of interest for this indication (e.g., age, gender, race, body weight, <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_6fbc57af-782c-454d-9206-5ff789fe7c5b"></a><a name="section-13.3"></a><p></p>
<h2>14.3 Treatment of DVT and PE and Reduction in the Risk of Recurrence of DVT and PE</h2>
<p class="First">Efficacy and safety of ELIQUIS for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following 6 to 12 months of anticoagulant treatment was derived from the AMPLIFY and AMPLIFY-EXT studies. Both studies were randomized, parallel-group, double-blind trials in patients with symptomatic proximal DVT and/or symptomatic PE. All key safety and efficacy endpoints were adjudicated in a blinded manner by an independent committee.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_c0b5a3ec-53fe-4d44-abdb-e463d3c0abe1"></a><a name="section-13.3.1"></a><p></p>
<h3><span class="Bold">AMPLIFY</span></h3>
<p class="First">The primary objective of AMPLIFY was to determine whether ELIQUIS was noninferior to enoxaparin/warfarin for the incidence of recurrent VTE (<span class="product-label-link" type="condition" conceptid="318775" conceptname="Venous embolism">venous thromboembolism</span>) or VTE-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Patients with an objectively confirmed symptomatic DVT and/or PE were randomized to treatment with ELIQUIS 10 mg twice daily orally for 7 days followed by ELIQUIS 5 mg twice daily orally for 6 months, or enoxaparin 1 mg/kg twice daily subcutaneously for at least 5 days (until INR â‰¥2) followed by warfarin (target INR range 2.0-3.0) orally for 6 months. Patients who required thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent, and patients with creatinine clearance &lt;25 mL/min, significant liver disease, an existing heart valve or <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, or active <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> were excluded from the AMPLIFY study. Patients were allowed to enter the study with or without prior parenteral anticoagulation (up to 48 hours).</p>
<p>A total of 5244 patients were evaluable for efficacy and were followed for a mean of 154 days in the ELIQUIS group and 152 days in the enoxaparin/warfarin group. The mean age was 57 years. The AMPLIFY study population was 59% male, 83% Caucasian, 8% Asian, and 4% Black. For patients randomized to warfarin, the mean percentage of time in therapeutic range (INR 2.0-3.0) was 60.9%.</p>
<p>Approximately 90% of patients enrolled in AMPLIFY had an unprovoked DVT or PE at baseline. The remaining 10% of patients with a provoked DVT or PE were required to have an additional ongoing risk factor in order to be randomized, which included previous episode of DVT or PE, immobilization, history of cancer, active cancer, and known prothrombotic genotype.</p>
<p>ELIQUIS was shown to be noninferior to enoxaparin/warfarin in the AMPLIFY study for the primary endpoint of recurrent symptomatic VTE (nonfatal DVT or nonfatal PE) or VTE-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> over 6 months of therapy (Table 13).</p>
<a name="_RefID0EZHBI"></a><table width="100%">
<caption><span>Table 13:Â Â Â Â Â Efficacy Results in the AMPLIFY Study</span></caption>
<col width="25%">
<col width="20%">
<col width="21%">
<col width="34%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top"></th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">N=2609 </span><br><span class="Bold">n</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Enoxaparin/Warfarin </span><br><span class="Bold">N=2635 </span><br><span class="Bold">n</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Relative Risk </span><br><span class="Bold">(95% CI)</span>
</th>
</tr></thead>
<tfoot>
<tr class="First"><td class="Botrule" align="left" colspan="4" valign="top">*Â Â Â Noninferior compared to enoxaparin/warfarin (P-value &lt;0.0001).</td></tr>
<tr class="Last"><td class="Botrule" align="left" colspan="4" valign="top">
<span class="Sup">â€ </span>Â Â Â Events associated with each endpoint were counted once per subject, but subjects may have contributed events to multiple endpoints.</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td class="Toprule"><p class="First">VTE or VTE-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>*</p></td>
<td class="Toprule" align="center"><p class="First">59 (2.3%)</p></td>
<td class="Toprule" align="center"><p class="First">71 (2.7%)</p></td>
<td class="Toprule" align="center"><p class="First">0.84 (0.60, 1.18)</p></td>
</tr>
<tr>
<td><p class="First">Â Â Â DVT<span class="Sup">â€ </span></p></td>
<td align="center"><p class="First">22 (0.8%)</p></td>
<td align="center"><p class="First">35 (1.3%)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â PE<span class="Sup">â€ </span></p></td>
<td align="center"><p class="First">27 (1.0%)</p></td>
<td align="center"><p class="First">25 (0.9%)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">Â Â Â VTE-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span><span class="Sup">â€ </span></p></td>
<td align="center"><p class="First">12 (0.4%)</p></td>
<td align="center"><p class="First">16 (0.6%)</p></td>
<td></td>
</tr>
<tr>
<td><p class="First">VTE or all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td align="center"><p class="First">84 (3.2%)</p></td>
<td align="center"><p class="First">104 (4.0%)</p></td>
<td align="center"><p class="First">0.82 (0.61, 1.08)</p></td>
</tr>
<tr class="Last">
<td class="Botrule"><p class="First">VTE or CV-related <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule" align="center"><p class="First">61 (2.3%)</p></td>
<td class="Botrule" align="center"><p class="First">77 (2.9%)</p></td>
<td class="Botrule" align="center"><p class="First">0.80 (0.57, 1.11)</p></td>
</tr>
</tbody>
</table>
<p>In the AMPLIFY study, patients were stratified according to their index event of PE (with or without DVT) or DVT (without PE). Efficacy in the initial treatment of VTE was consistent between the two subgroups.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="ID_22156e98-e10c-4d8a-be6c-83b87f18920c"></a><a name="section-13.3.2"></a><p></p>
<h3><span class="Bold">AMPLIFY-EXT</span></h3>
<p class="First">Patients who had been treated for DVT and/or PE for 6 to 12 months with anticoagulant therapy without having a recurrent event were randomized to treatment with ELIQUIS 2.5 mg orally twice daily, ELIQUIS 5 mg orally twice daily, or placebo for 12 months. Approximately one-third of patients participated in the AMPLIFY study prior to enrollment in the AMPLIFY-EXT study.</p>
<p>A total of 2482 patients were randomized to study treatment and were followed for a mean of approximately 330 days in the ELIQUIS group and 312 days in the placebo group. The mean age in the AMPLIFY-EXT study was 57 years. The study population was 57% male, 85% Caucasian, 5% Asian, and 3% Black.</p>
<p>The AMPLIFY-EXT study enrolled patients with either an unprovoked DVT or PE at baseline (approximately 92%) or patients with a provoked baseline event and one additional risk factor for recurrence (approximately 8%). However, patients who had experienced multiple episodes of unprovoked DVT or PE were excluded from the AMPLIFY-EXT study. In the AMPLIFY-EXT study, both doses of ELIQUIS were superior to placebo in the primary endpoint of symptomatic, recurrent VTE (nonfatal DVT or nonfatal PE), or all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (Table 14).</p>
<a name="_RefID0ENMBI"></a><table width="100%">
<caption><span>Table 14:Â Â Â Â Â Efficacy Results in the AMPLIFY-EXT Study</span></caption>
<col width="19%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="15%">
<col width="21%">
<thead>
<tr class="First">
<th class="Rrule Toprule" align="left" valign="top"></th>
<th class="Lrule Toprule" align="left" valign="top"></th>
<th class="Toprule" align="left" valign="top"></th>
<th class="Rrule Toprule" align="left" valign="top"></th>
<th class="Lrule Toprule" align="left" colspan="2" valign="top"><span class="Bold">Relative Risk (95% CI)</span></th>
</tr>
<tr class="Last">
<th class="Botrule Rrule" align="left" valign="top"></th>
<th class="Botrule Lrule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">2.5 mg</span><br><span class="Bold">N=840</span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">5 mg </span><br><span class="Bold">N=813</span>
</th>
<th class="Botrule Rrule" align="left" valign="top">
<span class="Bold">Placebo</span><br><br><span class="Bold">N=829</span>
</th>
<th class="Botrule Lrule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">2.5 mg </span><br><span class="Bold">vs Placebo</span>
</th>
<th class="Botrule" align="left" valign="top">
<span class="Bold">ELIQUIS </span><br><span class="Bold">5 mg </span><br><span class="Bold">vs Placebo</span>
</th>
</tr>
</thead>
<tfoot><tr class="First Last"><td class="Botrule" align="left" colspan="6" valign="top">*Â Â Â Patients with more than one event are counted in multiple rows.</td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Botrule Rrule Toprule"></td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3"><p class="First">n (%)</p></td>
<td class="Botrule Lrule Toprule"></td>
<td class="Botrule Toprule"></td>
</tr>
<tr>
<td class="Rrule"><p class="First">Recurrent VTE or all-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Lrule" align="center"><p class="First">32 (3.8)</p></td>
<td align="center"><p class="First">34 (4.2)</p></td>
<td class="Rrule" align="center"><p class="First">96 (11.6)</p></td>
<td class="Lrule" align="center"><p class="First">0.33 (0.22, 0.48)<br>p&lt;0.0001</p></td>
<td align="center"><p class="First">0.36 (0.25, 0.53)<br>p&lt;0.0001</p></td>
</tr>
<tr>
<td class="Rrule"><p class="First">Â Â Â DVT*</p></td>
<td class="Lrule" align="center"><p class="First">19 (2.3)</p></td>
<td align="center"><p class="First">28 (3.4)</p></td>
<td class="Rrule" align="center"><p class="First">72 (8.7)</p></td>
<td class="Lrule"></td>
<td></td>
</tr>
<tr>
<td class="Rrule"><p class="First">Â Â Â PE*</p></td>
<td class="Lrule" align="center"><p class="First">23 (2.7)</p></td>
<td align="center"><p class="First">25 (3.1)</p></td>
<td class="Rrule" align="center"><p class="First">37 (4.5)</p></td>
<td class="Lrule"></td>
<td></td>
</tr>
<tr class="Last">
<td class="Botrule Rrule"><p class="First">Â Â Â All-cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span></p></td>
<td class="Botrule Lrule" align="center"><p class="First">22 (2.6)</p></td>
<td class="Botrule" align="center"><p class="First">25 (3.1)</p></td>
<td class="Botrule Rrule" align="center"><p class="First">33 (4.0)</p></td>
<td class="Botrule Lrule"></td>
<td class="Botrule"></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_9978b025-12c2-47f3-8cfc-ee6e9f49eb3c"></a><a name="section-14.1"></a><p></p>
<div class="Section" data-sectionCode="34069-5">
<a name="ID_b316b44c-8742-4191-8b4e-7041b6fd9150"></a><a name="section-14.1.1"></a><p></p>
<h3><span class="Bold">How Supplied</span></h3>
<p class="First">ELIQUIS (apixaban) tablets are available as listed in the table below.</p>
<table width="100%">
<col width="10%">
<col width="18%">
<col width="24%">
<col width="25%">
<col width="24%">
<thead><tr class="First Last">
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Tablet </span><br><span class="Bold">Strength</span>
</th>
<th class="Botrule Toprule" align="left" valign="top">
<span class="Bold">Tablet</span><br><span class="Bold">Color/Shape</span>
</th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Tablet Markings</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">Package Size</span></th>
<th class="Botrule Toprule" align="left" valign="top"><span class="Bold">NDC Code</span></th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Botrule Toprule" align="center" rowspan="3"><p class="First">2.5 mg</p></td>
<td class="Botrule Toprule" rowspan="3"><p class="First">Yellow, round, biconvex</p></td>
<td class="Botrule Toprule" rowspan="3"><p class="First">Debossed with â€œ893â€? on one side and â€œ2Â½â€? on the other side</p></td>
<td class="Toprule" align="center"><p class="First">Bottles of 60</p></td>
<td class="Toprule" align="center"><p class="First">0003-0893-21</p></td>
</tr>
<tr>
<td align="center"><p class="First">Bottles of 180</p></td>
<td align="center"><p class="First">0003-0893-41</p></td>
</tr>
<tr>
<td class="Botrule" align="center"><p class="First">Hospital Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> <br>Package of 100</p></td>
<td class="Botrule" align="center"><p class="First">0003-0893-31</p></td>
</tr>
<tr>
<td class="Botrule" align="center" rowspan="3"><p class="First">5 mg</p></td>
<td class="Botrule" rowspan="3"><p class="First">Pink, oval, biconvex</p></td>
<td class="Botrule" rowspan="3"><p class="First">Debossed with â€œ894â€? on one side and â€œ5â€? on the other side</p></td>
<td align="center"><p class="First">Bottles of 60</p></td>
<td align="center"><p class="First">0003-0894-21</p></td>
</tr>
<tr>
<td align="center"><p class="First">Bottles of 180</p></td>
<td align="center"><p class="First">0003-0894-41</p></td>
</tr>
<tr class="Last">
<td class="Botrule" align="center"><p class="First">Hospital Unit-Dose <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> <br>Package of 100</p></td>
<td class="Botrule" align="center"><p class="First">0003-0894-31</p></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_9e9c7c6f-f22d-440e-9d0f-964fb9e8c9a2"></a><a name="section-14.2"></a><p></p>
<div class="Section" data-sectionCode="44425-7">
<a name="ID_fe980c51-5e0e-436e-8443-c2f506f6e187"></a><a name="section-14.2.1"></a><p></p>
<h3><span class="Bold">Storage and Handling</span></h3>
<p class="First">Store at 20Â°C to 25Â°C (68Â°F-77Â°F); excursions permitted between 15Â°C and 30Â°C (59Â°F-86Â°F) [see USP Controlled Room Temperature].</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s17"></a><a name="section-15"></a><p></p>
<h1>17  PATIENT COUNSELING INFORMATION</h1>
<p class="First"><span class="Italics">See FDA-approved patient labeling (Medication Guide).</span></p>
<p>Advise patients of the following:</p>
<dl>
<dt>â€¢</dt>
<dd>They should not discontinue ELIQUIS without talking to their physician first.</dd>
<dt>â€¢</dt>
<dd>They should be informed that it might take longer than usual for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop, and they may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> or bleed more easily when treated with ELIQUIS. Advise patients about how to recognize <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or symptoms of <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">hypovolemia</span> and of the urgent need to report any unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to their physician.</dd>
<dt>â€¢</dt>
<dd>They should tell their physicians and dentists they are taking ELIQUIS, and/or any other product known to affect <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> (including nonprescription products, such as aspirin or NSAIDs), before any surgery or medical or dental procedure is scheduled and before any new drug is taken.</dd>
<dt>â€¢</dt>
<dd>If the patient is having neuraxial anesthesia or spinal puncture, inform the patient to watch for signs and symptoms of spinal or <span class="product-label-link" type="condition" conceptid="4176148" conceptname="Extradural intracranial hematoma">epidural hematomas</span>, such as <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> of the legs, or bowel or bladder dysfunction <span class="Italics">[see <a href="#ID_55d4107b-3fc3-4715-b1c9-1f3e9060780e">Warnings and Precautions (5.3)</a>]</span>. If any of these symptoms occur, the patient should contact his or her physician immediately.</dd>
<dt>â€¢</dt>
<dd>They should tell their physicians if they are pregnant or plan to become pregnant or are breastfeeding or intend to breastfeed during treatment with ELIQUIS <span class="Italics">[see <a href="#ID_47163af8-a468-4113-acd7-e6f01f361d71">Use in Specific Populations (8.1</a></span>, <span class="Italics"><a href="#ID_49c34a2e-e9f2-40b3-94d0-9c14d350890b">8.3)</a>]</span>.</dd>
<dt>â€¢</dt>
<dd>If a dose is missed, the dose should be taken as soon as possible on the same day and twice-daily administration should be resumed. The dose should not be doubled to make up for a missed dose.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="sSign"></a><a name="section-16"></a><p></p>
<p class="First"><br><br>Manufactured by:<br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543 USA</p>
<p>Marketed by:<br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543 USA<br>and<br>Pfizer Inc<br>New York, New York 10017 USA</p>
<p>Rotachrom<span class="Sup">Â®</span> is a registered trademark of Diagnostica Stago.</p>
<p><br>1289808A1 / 1289807A1 / 1298500A1 <br><br><br><br></p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="ID_8eaa6df2-2d9a-4e43-94f6-b0dc66f2313b"></a><a name="section-17"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">ELIQUIS<span class="Sup">Â®</span></span> (ELL eh kwiss) <br><span class="Bold">(apixaban)</span><br><span class="Bold">tablets</span></p>
<p><span class="Bold">What is the most important information I should know about ELIQUIS?</span></p>
<dl>
<dt>â€¢</dt>
<dd>
<span class="Bold">For people taking ELIQUIS for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>:</span><br><br>People with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span> (a type of irregular heartbeat) are at an increased risk of forming a blood clot in the heart, which can travel to the brain, causing a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>, or to other parts of the body. ELIQUIS lowers your chance of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> by helping to prevent clots from forming. If you stop taking ELIQUIS, you may have increased risk of forming a clot in your blood.<br><br><span class="Bold">Do not stop taking ELIQUIS without talking to the doctor who prescribes it for you. Stopping ELIQUIS increases your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span><br><br>ELIQUIS may need to be stopped, if possible, prior to surgery or a medical or dental procedure. Ask the doctor who prescribed ELIQUIS for you when you should stop taking it. Your doctor will tell you when you may start taking ELIQUIS again after your surgery or procedure. If you have to stop taking ELIQUIS, your doctor may prescribe another medicine to help prevent a blood clot from forming.<br><br>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">ELIQUIS can cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span></span> which can be serious and rarely may lead to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. This is because ELIQUIS is a blood thinner medicine that reduces blood clotting.<br><br>You may have a higher risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> if you take ELIQUIS and take other medicines that increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, including:<br><dl>
<dt>â€¢</dt>
<dd>aspirin or aspirin-containing products</dd>
<dt>â€¢</dt>
<dd>long-term (chronic) use of nonsteroidal anti-inflammatory drugs (NSAIDs)</dd>
<dt>â€¢</dt>
<dd>warfarin sodium (COUMADIN<span class="Sup">Â®</span>, JANTOVEN<span class="Sup">Â®</span>)</dd>
<dt>â€¢</dt>
<dd>any medicine that contains heparin</dd>
<dt>â€¢</dt>
<dd>selective serotonin reuptake inhibitors (SSRIs) or serotonin norepinephrine reuptake inhibitors (SNRIs)</dd>
<dt>â€¢</dt>
<dd>other medicines to help prevent or treat blood clots</dd>
</dl>
</dd>
<dt>Â </dt>
<dd>
<br>Tell your doctor if you take any of these medicines. Ask your doctor or pharmacist if you are not sure if your medicine is one listed above.<br><br>While taking ELIQUIS:<dl>
<dt>â€¢</dt>
<dd>you may <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruise</span> more easily</dd>
<dt>â€¢</dt>
<dd>it may take longer than usual for any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> to stop</dd>
</dl>
</dd>
<dt>Â </dt>
<dd>
<br><span class="Bold">Call your doctor or get medical help right away if you have any of these signs or symptoms of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> when taking ELIQUIS:</span><br><br><dl>
<dt>â€¢</dt>
<dd>unexpected <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that lasts a long time, such as: <dl>
<dt>â€¢</dt>
<dd>unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> from the gums</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">nosebleeds</span> that happen often</dd>
<dt>â€¢</dt>
<dd>menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">vaginal bleeding</span> that is heavier than normal</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> that is severe or you cannot control</dd>
<dt>â€¢</dt>
<dd>red, pink, or brown urine</dd>
<dt>â€¢</dt>
<dd>red or <span class="product-label-link" type="condition" conceptid="4148536" conceptname="Dark stools">black stools</span> (looks like tar)</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> up blood or blood clots</dd>
<dt>â€¢</dt>
<dd>vomit blood or your vomit looks like coffee grounds</dd>
<dt>â€¢</dt>
<dd>unexpected <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, or <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span></dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, feeling dizzy or weak</dd>
</dl>
</dd>
<dt>â€¢</dt>
<dd><span class="Bold">ELIQUIS is not for patients with artificial heart valves.</span></dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Spinal or epidural blood clots (<span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>).</span> People who take a blood thinner medicine (anticoagulant) like ELIQUIS, and have medicine injected into their spinal and epidural area, or have a spinal puncture have a risk of forming a blood clot that can cause long-term or permanent loss of the ability to move (<span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>). Your risk of developing a spinal or epidural blood clot is higher if:<dl>
<dt>â€¢</dt>
<dd>a thin tube called an epidural catheter is placed in your back to give you certain medicine</dd>
<dt>â€¢</dt>
<dd>you take NSAIDs or a medicine to prevent blood from clotting</dd>
<dt>â€¢</dt>
<dd>you have a history of difficult or repeated epidural or spinal punctures</dd>
<dt>â€¢</dt>
<dd>you have a history of problems with your spine or have had surgery on your spine</dd>
</dl>
</dd>
<dt>Â </dt>
<dd>
<br>If you take ELIQUIS and receive spinal anesthesia or have a spinal puncture, your doctor should watch you closely for symptoms of spinal or epidural blood clots or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>. Tell your doctor right away if you have <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, or <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, especially in your legs and feet.</dd>
</dl>
<p><span class="Bold">What is ELIQUIS?</span></p>
<p>ELIQUIS is a prescription medicine used to:</p>
<dl>
<dt>â€¢</dt>
<dd>reduce the risk of <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> and blood clots in people who have <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</dd>
<dt>â€¢</dt>
<dd>reduce the risk of forming a blood clot in the legs and lungs of people who have just had hip or knee replacement surgery.</dd>
<dt>â€¢</dt>
<dd>treat blood clots in the veins of your legs (<span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>) or lungs (<span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>), and reduce the risk of them occurring again.</dd>
</dl>
<p>It is not known if ELIQUIS is safe and effective in children.</p>
<p><span class="Bold">Who should not take ELIQUIS?</span></p>
<p><span class="Bold">Do not take ELIQUIS if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>currently have certain types of abnormal <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.</dd>
<dt>â€¢</dt>
<dd>have had a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to ELIQUIS. Ask your doctor if you are not sure.</dd>
</dl>
<p><span class="Bold">What should I tell my doctor before taking ELIQUIS?</span></p>
<p><span class="Bold">Before you take ELIQUIS, tell your doctor if you:</span></p>
<dl>
<dt>â€¢</dt>
<dd>have kidney or liver problems</dd>
<dt>â€¢</dt>
<dd>have any other medical condition</dd>
<dt>â€¢</dt>
<dd>have ever had <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> problems</dd>
<dt>â€¢</dt>
<dd>are pregnant or plan to become pregnant. It is not known if ELIQUIS will harm your unborn baby.</dd>
<dt>â€¢</dt>
<dd>are breastfeeding or plan to breastfeed. It is not known if ELIQUIS passes into your breast milk. You and your doctor should decide if you will take ELIQUIS or breastfeed. You should not do both.</dd>
</dl>
<p>Tell all of your doctors and dentists that you are taking ELIQUIS. They should talk to the doctor who prescribed ELIQUIS for you, before you have <span class="Bold">any</span> surgery, medical or dental procedure.</p>
<p><span class="Bold">Tell your doctor about all the medicines you take, including</span> prescription and over-the-counter medicines, vitamins, and herbal supplements. Some of your other medicines may affect the way ELIQUIS works. Certain medicines may increase your risk of <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span> when taken with ELIQUIS. See "<span class="Bold">What is the most important information I should know about ELIQUIS?</span>"</p>
<p>Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get a new medicine.</p>
<p><span class="Bold">How should I take ELIQUIS?</span></p>
<dl>
<dt>â€¢</dt>
<dd><span class="Bold">Take ELIQUIS exactly as prescribed by your doctor.</span></dd>
<dt>â€¢</dt>
<dd>Take ELIQUIS twice every day with or without food.</dd>
<dt>â€¢</dt>
<dd>Do not change your dose or stop taking ELIQUIS unless your doctor tells you to.</dd>
<dt>â€¢</dt>
<dd>If you miss a dose of ELIQUIS, take it as soon as you remember. Do not take more than one dose of ELIQUIS at the same time to make up for a missed dose.</dd>
<dt>â€¢</dt>
<dd>Your doctor will decide how long you should take ELIQUIS. <span class="Bold">Do not stop taking it without first talking with your doctor. If you are taking ELIQUIS for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>, stopping ELIQUIS may increase your risk of having a <span class="product-label-link" type="condition" conceptid="381316" conceptname="Cerebrovascular accident">stroke</span>.</span>
</dd>
<dt>â€¢</dt>
<dd>
<span class="Bold">Do not run out of ELIQUIS. Refill your prescription before you run out.</span> When leaving the hospital following hip or knee replacement, be sure that you will have ELIQUIS available to avoid missing any doses.</dd>
<dt>â€¢</dt>
<dd>If you take too much ELIQUIS, call your doctor or go to the nearest hospital emergency room right away.</dd>
<dt>â€¢</dt>
<dd>Call your doctor or healthcare provider right away if you <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> or injure yourself, especially if you hit your head. Your doctor or healthcare provider may need to check you.</dd>
</dl>
<p><span class="Bold">What are the possible side effects of ELIQUIS?</span></p>
<dl>
<dt>â€¢</dt>
<dd>See "<span class="Bold">What is the most important information I should know about ELIQUIS?</span>"</dd>
<dt>â€¢</dt>
<dd>ELIQUIS can cause a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Call your doctor or get medical help right away if you have any of the following symptoms:<dl>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> or tightness</dd>
<dt>â€¢</dt>
<dd><span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of your face or tongue</dd>
<dt>â€¢</dt>
<dd>trouble breathing or <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span></dd>
<dt>â€¢</dt>
<dd>feeling dizzy or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">faint</span></dd>
</dl>
</dd>
</dl>
<p>Tell your doctor if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of ELIQUIS. For more information, ask your doctor or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store ELIQUIS?</span></p>
<p>Store ELIQUIS at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).</p>
<p><span class="Bold">Keep ELIQUIS and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about ELIQUIS</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use ELIQUIS for a condition for which it was not prescribed. Do not give ELIQUIS to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about ELIQUIS that is written for health professionals.</p>
<p>For more information, call 1-855-354-7847 (1-855-ELIQUIS) or go to www.ELIQUIS.com.</p>
<p><span class="Bold">What are the ingredients in ELIQUIS?</span></p>
<p>Active ingredient: apixaban.</p>
<p>Inactive ingredients: anhydrous lactose, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. The film coating contains lactose monohydrate, hypromellose, titanium dioxide, triacetin, and yellow iron oxide (2.5 mg tablets) or red iron oxide (5 mg tablets).</p>
<p>This Medication Guide has been approved by the U.S. Food and Drug Administration.<br><br><br><br>Manufactured by:<br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543 USA</p>
<p>Marketed by:<br>Bristol-Myers Squibb Company<br>Princeton, New Jersey 08543 USA<br>and<br>Pfizer Inc<br>New York, New York 10017 USA</p>
<p><br>COUMADIN<span class="Sup">Â®</span> is a registered trademark of Bristol-Myers Squibb Pharma Company.</p>
<p>All other trademarks are property of their respective companies.</p>
<p><br><br>1289808A1 / 1289807A1 / 1298500A1<br>1295958A1 <br><br>Revised August 2014<br><br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="ID_ebc987ea-417f-4c7f-a53b-7435c60e3454"></a><a name="section-18"></a><p></p>
<h1>Package/Label Display Panel</h1>
<p class="First">Eliquis Tablets 2.5 mg</p>
<p>Apixaban</p>
<p>10 Tablets</p>
<div class="Figure">
<a name="id684867402"></a><img alt="bag label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a454cd24-0c6d-46e8-b1e4-197388606175&amp;name=image-01.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ELIQUISÂ 		
					</strong><br><span class="contentTableReg">apixaban tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55154-0612(NDC:0003-0893)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>apixaban</strong> (apixaban) </td>
<td class="formItem">apixaban</td>
<td class="formItem">2.5Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>anhydrous lactose</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>croscarmellose sodium</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ferric oxide yellow</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">6mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">893;2;1;2</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55154-0612-0</td>
<td class="formItem">10  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA202155</td>
<td class="formItem">12/28/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Cardinal Health
							(188557102)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Cardinal Health</td>
<td class="formItem"></td>
<td class="formItem">188557102</td>
<td class="formItem">REPACK(55154-0612)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8fb1354e-ff24-4a62-b7a4-db46e652b3ce</div>
<div>Set id: a454cd24-0c6d-46e8-b1e4-197388606175</div>
<div>Version: 2</div>
<div>Effective Time: 20150401</div>
</div>
</div>Â <div class="DistributorName">Cardinal Health</div></p>
</body></html>
